<?xml version="1.0" encoding="UTF-8"?>
<aggregateKnowledgeResponse xmlns="http://www.w3.org/2005/Atom">
	<feed>
		<title>Management of stable chronic obstructive pulmonary disease</title>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C3540763" scheme="gov.nih.nlm.semanticType.phsu" label="various"/>
		<category term="C1274136" scheme="gov.nih.nlm.semanticType.topp" label="symptom control"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
		<category term="C0184633" scheme="gov.nih.nlm.semanticType.topp" label="oxygen therapy"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C0626910" scheme="gov.nih.nlm.semanticType.phsu" label="CAT"/>
		<category term="C1120833" scheme="gov.nih.nlm.semanticType.phsu" label="vital"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="Bronchodilators"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="Bronchodilators"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C1875809" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetic"/>
		<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium bromide"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0060657" scheme="gov.nih.nlm.semanticType.phsu" label="formoterol"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapies"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
		<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="aged"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C1722260" scheme="gov.nih.nlm.semanticType.phsu" label="indacaterol"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="Tiotropium"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="TIOtropium"/>
		<category term="C0557055" scheme="gov.nih.nlm.semanticType.hlca" label="reassuring"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0060657" scheme="gov.nih.nlm.semanticType.phsu" label="formoterol"/>
		<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C1722260" scheme="gov.nih.nlm.semanticType.phsu" label="indacaterol"/>
		<category term="C0001617" scheme="gov.nih.nlm.semanticType.horm" label="corticosteroids"/>
		<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="ICS"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
		<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
		<category term="C3652868" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone combination"/>
		<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
		<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="Prophylaxis"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparation"/>
		<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
		<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
		<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
		<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C2935023" scheme="gov.nih.nlm.semanticType.phsu" label="vilanterol"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="ICS"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="ICS"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0663772" scheme="gov.nih.nlm.semanticType.orch" label="VA"/>
		<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="ICS"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
		<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0034107" scheme="gov.nih.nlm.semanticType.hlca" label="pulse"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C2354695" scheme="gov.nih.nlm.semanticType.orch" label="gas"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0965618" scheme="gov.nih.nlm.semanticType.phsu" label="Roflumilast"/>
		<category term="C2267032" scheme="gov.nih.nlm.semanticType.phsu" label="PDE-4 inhibitor"/>
		<category term="C3502788" scheme="gov.nih.nlm.semanticType.phsu" label="PDE"/>
		<category term="C0965618" scheme="gov.nih.nlm.semanticType.phsu" label="Roflumilast"/>
		<category term="C0965618" scheme="gov.nih.nlm.semanticType.phsu" label="roflumilast"/>
		<category term="C0965618" scheme="gov.nih.nlm.semanticType.phsu" label="roflumilast"/>
		<category term="C0418986" scheme="gov.nih.nlm.semanticType.topp" label="respiratory medications"/>
		<category term="C0965618" scheme="gov.nih.nlm.semanticType.phsu" label="roflumilast"/>
		<category term="C1261322" scheme="gov.nih.nlm.semanticType.hlca" label="investigation"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0018305" scheme="gov.nih.nlm.semanticType.phsu" label="guaifenesin"/>
		<category term="C0063750" scheme="gov.nih.nlm.semanticType.phsu" label="iodinated glycerol"/>
		<category term="C0001047" scheme="gov.nih.nlm.semanticType.phsu" label="N-acetylcysteine"/>
		<category term="C0026698" scheme="gov.nih.nlm.semanticType.phsu" label="mucolytic"/>
		<category term="C0026698" scheme="gov.nih.nlm.semanticType.phsu" label="mucolytics"/>
		<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alfa"/>
		<category term="C3540763" scheme="gov.nih.nlm.semanticType.phsu" label="various"/>
		<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
		<category term="C0003240" scheme="gov.nih.nlm.semanticType.antb" label="macrolides"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0003451" scheme="gov.nih.nlm.semanticType.phsu" label="antiviral"/>
		<category term="C0280274" scheme="gov.nih.nlm.semanticType.topp" label="antiviral therapy"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C0184633" scheme="gov.nih.nlm.semanticType.topp" label="oxygen therapy"/>
		<category term="C0418996" scheme="gov.nih.nlm.semanticType.topp" label="long-term oxygen therapy"/>
		<category term="C0184633" scheme="gov.nih.nlm.semanticType.topp" label="oxygen therapy"/>
		<category term="C0418996" scheme="gov.nih.nlm.semanticType.topp" label="Long-term oxygen therapy"/>
		<category term="C0034107" scheme="gov.nih.nlm.semanticType.hlca" label="pulse"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
		<category term="C0032594" scheme="gov.nih.nlm.semanticType.phsu" label="polysaccharide"/>
		<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="Vaccinations"/>
		<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
		<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="Pneumococcal"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0021403" scheme="gov.nih.nlm.semanticType.imft" label="influenza vaccine"/>
		<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccination"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="medication therapy"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
		<category term="C0025175" scheme="gov.nih.nlm.semanticType.horm" label="megestrol"/>
		<category term="C0065879" scheme="gov.nih.nlm.semanticType.horm" label="megestrol acetate"/>
		<category term="C0376447" scheme="gov.nih.nlm.semanticType.phsu" label="appetite stimulant"/>
		<category term="C0700004" scheme="gov.nih.nlm.semanticType.horm" label="Megace"/>
		<category term="C1451216" scheme="gov.nih.nlm.semanticType.orch" label="acetate"/>
		<category term="C3536952" scheme="gov.nih.nlm.semanticType.phsu" label="stimulant"/>
		<category term="C0003402" scheme="gov.nih.nlm.semanticType.phsu" label="antioxidants"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0003402" scheme="gov.nih.nlm.semanticType.phsu" label="antioxidant"/>
		<category term="C0024128" scheme="gov.nih.nlm.semanticType.topp" label="lung transplantation"/>
		<category term="C0375931" scheme="gov.nih.nlm.semanticType.topp" label="lung volume reduction surgery"/>
		<category term="C0519107" scheme="gov.nih.nlm.semanticType.topp" label="lung volume reduction"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C0375931" scheme="gov.nih.nlm.semanticType.topp" label="lung volume reduction surgery"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0519107" scheme="gov.nih.nlm.semanticType.topp" label="lung volume reduction"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C0024128" scheme="gov.nih.nlm.semanticType.topp" label="lung transplantation"/>
		<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="referral"/>
		<category term="C0040732" scheme="gov.nih.nlm.semanticType.topp" label="transplant"/>
		<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="morphine"/>
		<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="Morphine"/>
		<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="morphine"/>
		<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparations"/>
		<category term="C0012306" scheme="gov.nih.nlm.semanticType.phsu" label="hydromorphone"/>
		<category term="C0015846" scheme="gov.nih.nlm.semanticType.phsu" label="fentanyl"/>
		<category term="C0030049" scheme="gov.nih.nlm.semanticType.phsu" label="oxycodone"/>
		<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="morphine"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive behavioral therapy"/>
		<category term="C0033978" scheme="gov.nih.nlm.semanticType.phsu" label="psychoactive agents"/>
		<category term="C3536778" scheme="gov.nih.nlm.semanticType.phsu" label="Respiratory stimulants"/>
		<category term="C3536952" scheme="gov.nih.nlm.semanticType.phsu" label="stimulants"/>
		<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
		<category term="C3540763" scheme="gov.nih.nlm.semanticType.phsu" label="various"/>
		<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0184633" scheme="gov.nih.nlm.semanticType.topp" label="oxygen therapy"/>
		<category term="C0418996" scheme="gov.nih.nlm.semanticType.topp" label="long-term oxygen therapy"/>
		<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccination"/>
		<category term="C0032594" scheme="gov.nih.nlm.semanticType.phsu" label="polysaccharide"/>
		<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
		<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="pneumococcal"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<id>1447</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H2"/>
			<id>207032</id>
			<summary>
				<section label="GENERAL APPROACH" id="2">
					<fragment>We share the philosophy of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) that pharmacologic and nonpharmacologic therapies should be guided by disease severity and aim to control symptoms, decrease exacerbations, and improve patient function and quality of life.</fragment>
				</section>
			</summary>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H2"/>
			<id>207033</id>
			<summary>
				<section label="GENERAL APPROACH" id="2">
					<fragment>Both pharmacologic and non-pharmacologic interventions are key to the management of COPD patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H2"/>
			<id>207035</id>
			<summary>
				<section label="GENERAL APPROACH" id="2">
					<fragment>In the discussion that follows, the formal assessment of COPD severity, the various therapies for COPD, and the clinical evidence for each therapy are reviewed.</fragment>
				</section>
			</summary>
			<category term="C3540763" scheme="gov.nih.nlm.semanticType.phsu" label="various"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H2"/>
			<id>207037</id>
			<summary>
				<section label="GENERAL APPROACH" id="2">
					<fragment>However, for patients who present with severe disease, a stepwise approach may not always be the best choice, as it may be necessary to initiate several medications at once to achieve symptom control.</fragment>
				</section>
			</summary>
			<category term="C1274136" scheme="gov.nih.nlm.semanticType.topp" label="symptom control"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H2"/>
			<id>207038</id>
			<summary>
				<section label="GENERAL APPROACH" id="2">
					<fragment>An approach to the management of patients with stable COPD is outlined below.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H2"/>
			<id>207042</id>
			<summary>
				<section label="GENERAL APPROACH" id="2">
					<fragment>The oral bronchodilator theophylline, which is only modestly effective and has more side effects than inhaled bronchodilators, is occasionally used for patients with refractory COPD;</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H2"/>
			<id>207045</id>
			<summary>
				<section label="GENERAL APPROACH" id="2">
					<fragment>Mucoactive agents are now rarely used and chronic systemic glucocorticoids are not recommended.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H2"/>
			<id>207046</id>
			<summary>
				<section label="GENERAL APPROACH" id="2">
					<fragment>Smoking cessation is a crucial step in the management of all patients with COPD.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H2"/>
			<id>207047</id>
			<summary>
				<section label="GENERAL APPROACH" id="2">
					<fragment>Pulmonary rehabilitation also has a major role in the management of COPD, and supplemental oxygen therapy improves mortality in patients with significant hypoxemia at rest.</fragment>
				</section>
			</summary>
			<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
			<category term="C0184633" scheme="gov.nih.nlm.semanticType.topp" label="oxygen therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H2"/>
			<id>207048</id>
			<summary>
				<section label="GENERAL APPROACH" id="2">
					<fragment>In order to determine whether the patient has achieved an adequate response to therapy, it is necessary to monitor symptoms (dyspnea, activity tolerance), the amount of as-needed medication use, health status, the frequency of exacerbations, and lung function (ie, airflow limitation on spirometry).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H3"/>
			<id>207049</id>
			<summary>
				<section label="ASSESSING DISEASE SEVERITY" id="3">
					<fragment>A multi-component staging system for COPD severity has been developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) that categorizes disease severity based on (1) symptoms (based on modified Medical Research Council dyspnea scale or COPD Assessment Test [CAT]), (2) the severity of airflow limitation (based on the forced expiratory volume in one second [FEV 1] percent predicted) among patients with a ratio of FEV1 to forced vital capacity (FEV1/FVC) &lt;0.7, and (3) risk of exacerbations.</fragment>
				</section>
			</summary>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="C0626910" scheme="gov.nih.nlm.semanticType.phsu" label="CAT"/>
			<category term="C1120833" scheme="gov.nih.nlm.semanticType.phsu" label="vital"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H3"/>
			<id>207058</id>
			<summary>
				<section label="ASSESSING DISEASE SEVERITY" id="3">
					<fragment>This categorization system is also used as a guide for the management of patients with stable COPD.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H3"/>
			<id>207059</id>
			<summary>
				<section label="ASSESSING DISEASE SEVERITY" id="3">
					<fragment>The multidimensional BODE index may be used to assess an individual's risk of death or hospitalization due to COPD );</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H4"/>
			<id>207061</id>
			<summary>
				<section label="BRONCHODILATORS" id="4">
					<fragment>Bronchodilators are the therapeutic mainstay for patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="Bronchodilators"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H4"/>
			<id>207063</id>
			<summary>
				<section label="BRONCHODILATORS" id="4">
					<fragment>Bronchodilators have been consistently shown to induce long-term improvements in symptoms, exercise capacity, and airflow limitation, even when there is no spirometric improvement following a single test dose.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="Bronchodilators"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H4"/>
			<id>207065</id>
			<summary>
				<section label="BRONCHODILATORS" id="4">
					<fragment>All symptomatic patients with COPD should be prescribed a short-acting bronchodilator to be used on an as-needed basis.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H5"/>
			<id>207073</id>
			<summary>
				<section label="acting bronchodilators" id="5">
					<fragment>The first decision that most clinicians face when managing a patient with COPD is which short-acting bronchodilator is most appropriate in a patient with mild intermittent symptoms.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H5"/>
			<id>207075</id>
			<summary>
				<section label="acting bronchodilators" id="5">
					<fragment>All of the short-acting bronchodilators improve lung function and symptoms.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H6"/>
			<id>207081</id>
			<summary>
				<section label="Beta agonists" id="6">
					<fragment>In general, short-acting beta agonists are prescribed on an as-needed basis, rather than regularly scheduled, in order to decrease sympathomimetic exposure in patients with less severe symptoms.</fragment>
				</section>
			</summary>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C1875809" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetic"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H6"/>
			<id>207082</id>
			<summary>
				<section label="Beta agonists" id="6">
					<fragment>One trial randomly assigned 53 patients with COPD to receive regularly scheduled albuterol or placebo, while continuing ipratropium bromide, inhaled glucocorticoid, and as-needed albuterol.</fragment>
				</section>
			</summary>
			<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium bromide"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H6"/>
			<id>207083</id>
			<summary>
				<section label="Beta agonists" id="6">
					<fragment>Regularly scheduled albuterol doubled the total amount of albuterol received without a clinically significant impact on lung function, symptoms, or exercise capacity.</fragment>
				</section>
			</summary>
			<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H6"/>
			<id>207085</id>
			<summary>
				<section label="Beta agonists" id="6">
					<fragment>However, in a nested case control study of 76,661 patients with COPD, the rate of severe cardiac arrhythmia was elevated among those with new use of oral or inhaled short-acting beta agonist (RR 1.27, 95% CI 1.03-1.57).</fragment>
				</section>
			</summary>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H6"/>
			<id>207092</id>
			<summary>
				<section label="Beta agonists" id="6">
					<fragment>Hypokalemia can also occur in extreme cases and should be monitored in patients at risk.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H7"/>
			<id>207094</id>
			<summary>
				<section label="Anticholinergics" id="7">
					<fragment>Short-acting anticholinergic medications improve lung function and symptoms.</fragment>
				</section>
			</summary>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H7"/>
			<id>207095</id>
			<summary>
				<section label="Anticholinergics" id="7">
					<fragment>As an example, one double-blind trial randomly assigned 183 patients with moderate to severe COPD to receive ipratropium alone (80 mcg, three times per day), formoterol, or placebo for 12 weeks.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0060657" scheme="gov.nih.nlm.semanticType.phsu" label="formoterol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H7"/>
			<id>207096</id>
			<summary>
				<section label="Anticholinergics" id="7">
					<fragment>Short-acting beta agonists were permitted as-needed for relief of acute dyspnea.</fragment>
				</section>
			</summary>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H8"/>
			<id>207100</id>
			<summary>
				<section label="Comparison" id="8">
					<fragment>On average, both medications improve lung function to a similar degree.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H9"/>
			<id>207103</id>
			<summary>
				<section label="Combination therapy" id="9">
					<fragment>As an example, the largest trial randomly assigned 534 patients with COPD to receive albuterol alone, ipratropium alone, or combination therapy (albuterol plus ipratropium).</fragment>
				</section>
			</summary>
			<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H9"/>
			<id>207105</id>
			<summary>
				<section label="Combination therapy" id="9">
					<fragment>A similar study reported that combination therapy decreased the frequency of exacerbation compared to albuterol, but not ipratropium.</fragment>
				</section>
			</summary>
			<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H10"/>
			<id>207106</id>
			<summary>
				<section label="acting bronchodilators" id="10">
					<fragment>Short-acting bronchodilators alone or in combination may be insufficient to control symptoms and are not considered to be maintenance therapies.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapies"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H10"/>
			<id>207107</id>
			<summary>
				<section label="acting bronchodilators" id="10">
					<fragment>A regularly scheduled long-acting inhaled bronchodilator is added in these patients, who have more advanced disease in the range of GOLD category B and higher.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H10"/>
			<id>207112</id>
			<summary>
				<section label="acting bronchodilators" id="10">
					<fragment>The use of theophylline is usually limited to an add-on therapy when symptoms continue in patients with more severe disease despite the use of other treatments.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H11"/>
			<id>207116</id>
			<summary>
				<section label="Beta agonists" id="11">
					<fragment>Multiple studies have demonstrated the benefit of LABAs in patients with stable COPD.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H11"/>
			<id>207117</id>
			<summary>
				<section label="Beta agonists" id="11">
					<fragment>The largest trial of salmeterol, Toward a Revolution in COPD Health (TORCH), randomly assigned 6112 patients with mostly severe COPD (mean FEV1 44 percent of predicted ) to one of four treatment arms for three years: salmeterol alone (50 mcg twice daily), fluticasone alone (500 mcg twice daily), combination therapy (salmeterol plus fluticasone), or placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
			<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H11"/>
			<id>207120</id>
			<summary>
				<section label="Beta agonists" id="11">
					<fragment>The potential association of hospitalization or death due to a cardiac arrhythmia and use of LABAs was examined in a nested case control study of 76,661 patients aged &gt;=67 years with COPD.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="aged"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H11"/>
			<id>207131</id>
			<summary>
				<section label="Beta agonists" id="11">
					<fragment>The largest trial randomly assigned 1683 patients with moderate-to-severe COPD to once daily indacaterol 150 or 300 mcg, placebo, or tiotropium.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C1722260" scheme="gov.nih.nlm.semanticType.phsu" label="indacaterol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H12"/>
			<id>207141</id>
			<summary>
				<section label="Anticholinergics" id="12">
					<fragment>Tiotropium, which has been studied the most, improves lung function and decreases dynamic hyperinflation (an effect also seen with other medications), while also decreasing dyspnea and exacerbations.</fragment>
				</section>
			</summary>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="Tiotropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H12"/>
			<id>207145</id>
			<summary>
				<section label="Anticholinergics" id="12">
					<fragment>Conflicting evidence has suggested possible adverse cardiovascular effects of anticholinergic therapy in patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H12"/>
			<id>207148</id>
			<summary>
				<section label="Anticholinergics" id="12">
					<fragment>However, a large randomized trial, the TIOtropium Safety and Performance In Respimat (TIOSPIR) trial, revealed no safety issues with the device and is reassuring about the safety of the Respimat device.</fragment>
				</section>
			</summary>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="TIOtropium"/>
			<category term="C0557055" scheme="gov.nih.nlm.semanticType.hlca" label="reassuring"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H13"/>
			<id>207158</id>
			<summary>
				<section label="Comparison" id="13">
					<fragment>In a nested case-control analysis, 26,628 patients age 66 or older with COPD who had a hospitalization or emergency room visit for a cardiovascular event were matched to controls with similar age and COPD severity who had no cardiovascular events.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H14"/>
			<id>207167</id>
			<summary>
				<section label="Combined therapy" id="14">
					<fragment>In patients with GOLD stage II-IV COPD whose symptoms are not well-controlled with a single long-acting bronchodilator, the addition of a second class of long acting bronchodilator may provide additional benefit.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H14"/>
			<id>207169</id>
			<summary>
				<section label="Combined therapy" id="14">
					<fragment>A meta-analysis of five trials (3263 participants) that assessed combination therapy with tiotropium (LAMA) plus a LABA (salmeterol, formoterol, or indacaterol) and found only a slightly better quality of life and a small increase in the post-bronchodilator FEV1 with the combination compared with tiotropium alone.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0060657" scheme="gov.nih.nlm.semanticType.phsu" label="formoterol"/>
			<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C1722260" scheme="gov.nih.nlm.semanticType.phsu" label="indacaterol"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H15"/>
			<id>207177</id>
			<summary>
				<section label="INHALED GLUCOCORTICOIDS" id="15">
					<fragment>Inhaled glucocorticoids (also known as inhaled corticosteroids or ICS) may reduce this inflammation.</fragment>
				</section>
			</summary>
			<category term="C0001617" scheme="gov.nih.nlm.semanticType.horm" label="corticosteroids"/>
			<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="ICS"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H15"/>
			<id>207178</id>
			<summary>
				<section label="INHALED GLUCOCORTICOIDS" id="15">
					<fragment>The available data, which are presented in detail separately, suggest that inhaled glucocorticoids decrease exacerbations and modestly slow the progression of respiratory symptoms, but appear to have little impact on lung function and mortality.</fragment>
				</section>
			</summary>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H15"/>
			<id>207180</id>
			<summary>
				<section label="INHALED GLUCOCORTICOIDS" id="15">
					<fragment>Adverse effects associated with inhaled glucocorticoids are discussed separately.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H16"/>
			<id>207181</id>
			<summary>
				<section label="BRONCHODILATORS PLUS INHALED GLUCOCORTICOIDS" id="16">
					<fragment>Inhaled glucocorticoids are typically used in combination with a long-acting bronchodilator for patients in GOLD stage III-IV, who have significant symptoms or repeated exacerbations, despite an optimal bronchodilator regimen.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H16"/>
			<id>207183</id>
			<summary>
				<section label="BRONCHODILATORS PLUS INHALED GLUCOCORTICOIDS" id="16">
					<fragment>Inhaled glucocorticoids are continued in patients whose symptoms, frequency of exacerbations, and/or lung function improve within one month.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H16"/>
			<id>207187</id>
			<summary>
				<section label="BRONCHODILATORS PLUS INHALED GLUCOCORTICOIDS" id="16">
					<fragment>Estimates of cost-effectiveness also favored the salmeterol-fluticasone combination over placebo or either of the individual agents.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
			<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
			<category term="C3652868" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone combination"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H16"/>
			<id>207192</id>
			<summary>
				<section label="BRONCHODILATORS PLUS INHALED GLUCOCORTICOIDS" id="16">
					<fragment>The second large trial of combination therapy (Investigating New Standards for Prophylaxis in Reduction of Exacerbations, INSPIRE) included 1323 patients with stable, mostly severe COPD (mean FEV1 39 percent of predicted ) who were randomly assigned to receive salmeterol plus fluticasone (50 and 500 microg/puff, respectively) or tiotropium alone for two years.</fragment>
				</section>
			</summary>
			<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
			<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="Prophylaxis"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H16"/>
			<id>207195</id>
			<summary>
				<section label="BRONCHODILATORS PLUS INHALED GLUCOCORTICOIDS" id="16">
					<fragment>Whether a lower strength preparation of fluticasone would have a similarly beneficial effect on mortality without the adverse effect on pneumonia is not known, although a prior study using the 250 microg strength of fluticasone in combination with salmeterol reported a similar increase in the number of pneumonias compared with salmeterol alone.</fragment>
				</section>
			</summary>
			<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparation"/>
			<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
			<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H16"/>
			<id>207199</id>
			<summary>
				<section label="BRONCHODILATORS PLUS INHALED GLUCOCORTICOIDS" id="16">
					<fragment>Food and Drug Administration for the treatment of COPD.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
			<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H16"/>
			<id>207204</id>
			<summary>
				<section label="BRONCHODILATORS PLUS INHALED GLUCOCORTICOIDS" id="16">
					<fragment>In a pooled analysis of two trials that compared combinations of vilanterol-fluticasone with vilanterol alone in 3255 patients with COPD, vilanterol 25 mcg with fluticasone 100 mcg or 200 mcg modestly reduced the yearly moderate and severe exacerbation rates more than vilanterol alone (RR 0.79, 95% CI 0.64-0.97, RR 0.69, 95% CI 0.56-0.85, respectively).</fragment>
				</section>
			</summary>
			<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C2935023" scheme="gov.nih.nlm.semanticType.phsu" label="vilanterol"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H16"/>
			<id>207206</id>
			<summary>
				<section label="BRONCHODILATORS PLUS INHALED GLUCOCORTICOIDS" id="16">
					<fragment>A question that has been less well studied is whether it would be preferable to add a second long-acting bronchodilator (from the alternate class) or an inhaled glucocorticoid in patients whose disease in not well-controlled with a single long-acting bronchodilator.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H33425476"/>
			<id>207212</id>
			<summary>
				<section label="TRIPLE INHALER THERAPY" id="33425476">
					<fragment>In patients with severe COPD, triple inhaler therapy with a long-acting beta agonist plus an inhaled glucocorticoid plus a long-acting anticholinergic is often used.</fragment>
				</section>
			</summary>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H33425476"/>
			<id>207215</id>
			<summary>
				<section label="TRIPLE INHALER THERAPY" id="33425476">
					<fragment>with two-thirds of the patients using an inhaled long acting beta agonist (LABA) and an inhaled glucocorticoid (ICS) as their usual care.</fragment>
				</section>
			</summary>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="ICS"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H33425476"/>
			<id>207216</id>
			<summary>
				<section label="TRIPLE INHALER THERAPY" id="33425476">
					<fragment>The addition of tiotropium to those patients receiving a LABA and an ICS as usual care significantly improved airflows, reduced exacerbations, and improved health related quality of life.</fragment>
				</section>
			</summary>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="ICS"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H33425476"/>
			<id>207217</id>
			<summary>
				<section label="TRIPLE INHALER THERAPY" id="33425476">
					<fragment>A retrospective study of two cohorts of patients with COPD cared for in the Veterans Affairs (VA) system compared a regimen of tiotropium plus inhaled LABA plus ICS to a historic, matched COPD population treated with an inhaled LABA plus ICS.</fragment>
				</section>
			</summary>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0663772" scheme="gov.nih.nlm.semanticType.orch" label="VA"/>
			<category term="C0960545" scheme="gov.nih.nlm.semanticType.orch" label="ICS"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H33425476"/>
			<id>207222</id>
			<summary>
				<section label="TRIPLE INHALER THERAPY" id="33425476">
					<fragment>Other studies have shown a benefit to triple therapy compared with single agent therapy in moderate to severe COPD: In a double-blind trial, 449 patients with moderate or severe COPD were randomly assigned to one of three treatment groups: tiotropium plus placebo, tiotropium plus salmeterol, or tiotropium plus both salmeterol and fluticasone for one year;</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
			<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H17"/>
			<id>207228</id>
			<summary>
				<section label="REFRACTORY DISEASE" id="17">
					<fragment>Some patients continue to have symptoms or repeated exacerbations of COPD despite therapy with an optimal long-acting inhaled bronchodilator plus an inhaled glucocorticoid (eg, GOLD III or IV).</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H17"/>
			<id>207230</id>
			<summary>
				<section label="REFRACTORY DISEASE" id="17">
					<fragment>When managing patients with refractory disease, we assess for exercise-related oxygen desaturation using pulse oximetry during ambulation.</fragment>
				</section>
			</summary>
			<category term="C0034107" scheme="gov.nih.nlm.semanticType.hlca" label="pulse"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H17"/>
			<id>207231</id>
			<summary>
				<section label="REFRACTORY DISEASE" id="17">
					<fragment>If desaturation occurs and is associated with symptoms, use of supplemental oxygen may reduce symptoms.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H17"/>
			<id>207233</id>
			<summary>
				<section label="REFRACTORY DISEASE" id="17">
					<fragment>A small number of carefully selected patients may benefit from surgical intervention.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19"/>
			<id>207238</id>
			<summary>
				<section label="Theophylline" id="19">
					<fragment>Similarly, in a randomized crossover trial of 60 patients with COPD, theophylline decreased dyspnea and improved gas exchange, lung function, and respiratory muscle function.</fragment>
				</section>
			</summary>
			<category term="C2354695" scheme="gov.nih.nlm.semanticType.orch" label="gas"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19"/>
			<id>207242</id>
			<summary>
				<section label="Theophylline" id="19">
					<fragment>Theophylline is metabolized in the liver and any process that interferes with liver function can rapidly change theophylline levels.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19"/>
			<id>207243</id>
			<summary>
				<section label="Theophylline" id="19">
					<fragment>In addition, many drugs can interact with theophylline, requiring close monitoring of drug levels and awareness of these issues.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19"/>
			<id>207244</id>
			<summary>
				<section label="Theophylline" id="19">
					<fragment>In general, patients with COPD can be adequately treated with serum levels in the 8 to 12 mcg/mL range.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H204741580"/>
			<id>207246</id>
			<summary>
				<section label="4 inhibitors" id="204741580">
					<fragment>Roflumilast is an oral, PDE-4 inhibitor that is approved for use in patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0965618" scheme="gov.nih.nlm.semanticType.phsu" label="Roflumilast"/>
			<category term="C2267032" scheme="gov.nih.nlm.semanticType.phsu" label="PDE-4 inhibitor"/>
			<category term="C3502788" scheme="gov.nih.nlm.semanticType.phsu" label="PDE"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H204741580"/>
			<id>207247</id>
			<summary>
				<section label="4 inhibitors" id="204741580">
					<fragment>The FDA approved indication is for the reduction of exacerbations in patients with chronic bronchitis, severe or very severe airflow limitation, and a history of exacerbations.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H204741580"/>
			<id>207249</id>
			<summary>
				<section label="4 inhibitors" id="204741580">
					<fragment>Roflumilast significantly improved prebronchodilator FEV1 and decreased the rate of moderate to severe exacerbations in a 52 week, randomized trial of 3091 patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0965618" scheme="gov.nih.nlm.semanticType.phsu" label="Roflumilast"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H204741580"/>
			<id>207253</id>
			<summary>
				<section label="4 inhibitors" id="204741580">
					<fragment>Side effects of nausea, diarrhea, and weight loss were more frequent in the roflumilast groups.</fragment>
				</section>
			</summary>
			<category term="C0965618" scheme="gov.nih.nlm.semanticType.phsu" label="roflumilast"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H204741580"/>
			<id>207254</id>
			<summary>
				<section label="4 inhibitors" id="204741580">
					<fragment>Although roflumilast is approved in the United States for COPD patients with a history of exacerbations, the magnitude of benefit on lung function is modest.</fragment>
				</section>
			</summary>
			<category term="C0965618" scheme="gov.nih.nlm.semanticType.phsu" label="roflumilast"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H204741580"/>
			<id>207257</id>
			<summary>
				<section label="4 inhibitors" id="204741580">
					<fragment>Whether roflumilast provides additional benefits when combined with other respiratory medications (eg, LABA/inhaled glucocorticoid combination) that are used to reduce COPD exacerbation frequency remains unknown and is currently under investigation.</fragment>
				</section>
			</summary>
			<category term="C0418986" scheme="gov.nih.nlm.semanticType.topp" label="respiratory medications"/>
			<category term="C0965618" scheme="gov.nih.nlm.semanticType.phsu" label="roflumilast"/>
			<category term="C1261322" scheme="gov.nih.nlm.semanticType.hlca" label="investigation"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H21"/>
			<id>207258</id>
			<summary>
				<section label="Systemic glucocorticoids" id="21">
					<fragment>Systemic glucocorticoids have long been used to treat exacerbations in patients with COPD;</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H21"/>
			<id>207260</id>
			<summary>
				<section label="Systemic glucocorticoids" id="21">
					<fragment>The roles of systemic glucocorticoids in the treatment of acute exacerbations of COPD and in chronic stable COPD are discussed in more detail separately.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H22"/>
			<id>207264</id>
			<summary>
				<section label="Mucoactive agents" id="22">
					<fragment>Thick, tenacious secretions can be a major problem in patients with COPD, but there is little evidence that thinning or increasing the clearance of secretions induces clinical improvement.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H22"/>
			<id>207265</id>
			<summary>
				<section label="Mucoactive agents" id="22">
					<fragment>Thus, mucoactive agents are not accepted as routine care for patients with stable COPD.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H22"/>
			<id>207266</id>
			<summary>
				<section label="Mucoactive agents" id="22">
					<fragment>Oral expectorants (eg, guaifenesin, iodides) offer little benefit to patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0018305" scheme="gov.nih.nlm.semanticType.phsu" label="guaifenesin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H22"/>
			<id>207267</id>
			<summary>
				<section label="Mucoactive agents" id="22">
					<fragment>As an example, one study demonstrated that iodinated glycerol improved cough and chest discomfort in some patients with chronic bronchitis;</fragment>
				</section>
			</summary>
			<category term="C0063750" scheme="gov.nih.nlm.semanticType.phsu" label="iodinated glycerol"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H22"/>
			<id>207270</id>
			<summary>
				<section label="Mucoactive agents" id="22">
					<fragment>N-acetylcysteine (NAC) is a mucolytic that purportedly thins the secretions of patients with chronic bronchitis.</fragment>
				</section>
			</summary>
			<category term="C0001047" scheme="gov.nih.nlm.semanticType.phsu" label="N-acetylcysteine"/>
			<category term="C0026698" scheme="gov.nih.nlm.semanticType.phsu" label="mucolytic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H22"/>
			<id>207277</id>
			<summary>
				<section label="Mucoactive agents" id="22">
					<fragment>Alternative mucolytics include dornase alfa (DNase), exogenous surfactant, various proteolytic agents, and various detergents.</fragment>
				</section>
			</summary>
			<category term="C0026698" scheme="gov.nih.nlm.semanticType.phsu" label="mucolytics"/>
			<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alfa"/>
			<category term="C3540763" scheme="gov.nih.nlm.semanticType.phsu" label="various"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H22"/>
			<id>207278</id>
			<summary>
				<section label="Mucoactive agents" id="22">
					<fragment>These agents require additional evaluation prior to their routine use in patients with COPD.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H22"/>
			<id>207280</id>
			<summary>
				<section label="Mucoactive agents" id="22">
					<fragment>Nebulized water or hypertonic saline is without documented benefit and may irritate the airways and induce bronchospasm.</fragment>
				</section>
			</summary>
			<category term="C1301725" scheme="gov.nih.nlm.semanticType.hlca" label="documented"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H23"/>
			<id>207281</id>
			<summary>
				<section label="Chronic antibiotic therapy" id="23">
					<fragment>Chronic antibiotic therapy is generally not indicated for the majority of patients with stable COPD (eg, emphysema, chronic bronchitis).</fragment>
				</section>
			</summary>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H23"/>
			<id>207282</id>
			<summary>
				<section label="Chronic antibiotic therapy" id="23">
					<fragment>However, certain antibiotics, macrolides in particular, may have antiinflammatory effects in addition to their antibiotic effect.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0003240" scheme="gov.nih.nlm.semanticType.antb" label="macrolides"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H23"/>
			<id>207283</id>
			<summary>
				<section label="Chronic antibiotic therapy" id="23">
					<fragment>For patients who continue to have frequent exacerbations despite optimal therapy for COPD with bronchodilators and antiinflammatory agents, we suggest antibiotic prophylaxis with azithromycin.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H23"/>
			<id>207285</id>
			<summary>
				<section label="Chronic antibiotic therapy" id="23">
					<fragment>Patients whose COPD is associated with bronchiectasis may benefit from chronic antibiotic therapy.</fragment>
				</section>
			</summary>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H23"/>
			<id>207287</id>
			<summary>
				<section label="Chronic antibiotic therapy" id="23">
					<fragment>Nonimmunized patients with COPD who are at high risk for contracting influenza and/or have early acute influenza infections may benefit from antiviral therapy.</fragment>
				</section>
			</summary>
			<category term="C0003451" scheme="gov.nih.nlm.semanticType.phsu" label="antiviral"/>
			<category term="C0280274" scheme="gov.nih.nlm.semanticType.topp" label="antiviral therapy"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H25"/>
			<id>207288</id>
			<summary>
				<section label="Oxygen" id="25">
					<fragment>Many patients with stable severe COPD (especially GOLD Stage IV disease) have chronic hypoxemia.</fragment>
				</section>
			</summary>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H25"/>
			<id>207289</id>
			<summary>
				<section label="Oxygen" id="25">
					<fragment>It is important that this be detected because long-term oxygen therapy improves survival and quality of life in hypoxemic patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0184633" scheme="gov.nih.nlm.semanticType.topp" label="oxygen therapy"/>
			<category term="C0418996" scheme="gov.nih.nlm.semanticType.topp" label="long-term oxygen therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H25"/>
			<id>207292</id>
			<summary>
				<section label="Oxygen" id="25">
					<fragment>Long-term oxygen therapy should be prescribed for all stable patients with COPD who have chronic hypoxemia at rest (PaO2 &lt;=55 mmHg or SpO2 &lt;=88 percent).</fragment>
				</section>
			</summary>
			<category term="C0184633" scheme="gov.nih.nlm.semanticType.topp" label="oxygen therapy"/>
			<category term="C0418996" scheme="gov.nih.nlm.semanticType.topp" label="Long-term oxygen therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H25"/>
			<id>207294</id>
			<summary>
				<section label="Oxygen" id="25">
					<fragment>Arterial blood gases and pulse oximetry are the only reliable methods of detecting hypoxemia in patients with COPD because most patients have few if any symptoms that can specifically be related to decreased oxygenation.</fragment>
				</section>
			</summary>
			<category term="C0034107" scheme="gov.nih.nlm.semanticType.hlca" label="pulse"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H25"/>
			<id>207297</id>
			<summary>
				<section label="Oxygen" id="25">
					<fragment>Supplemental oxygen is recommended for individuals whose in-flight PaO2 is expected to fall below 50 mmHg.</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H27"/>
			<id>207300</id>
			<summary>
				<section label="Smoking cessation" id="27">
					<fragment>Encouraging smoking cessation is essential because smoking cessation can reduce the rate of FEV1 decline that exists in smokers with COPD.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H28"/>
			<id>207305</id>
			<summary>
				<section label="Vaccinations" id="28">
					<fragment>Infection is a common cause of COPD exacerbation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H28"/>
			<id>207306</id>
			<summary>
				<section label="Vaccinations" id="28">
					<fragment>Vaccinations can prevent some infections and should be offered to patients with stable COPD: Pneumococcal polysaccharide vaccine should be offered to all patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0032594" scheme="gov.nih.nlm.semanticType.phsu" label="polysaccharide"/>
			<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="Vaccinations"/>
			<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
			<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="Pneumococcal"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H28"/>
			<id>207307</id>
			<summary>
				<section label="Vaccinations" id="28">
					<fragment>An annual influenza vaccine should be given to all patients, particularly those with COPD.</fragment>
				</section>
			</summary>
			<category term="C0021403" scheme="gov.nih.nlm.semanticType.imft" label="influenza vaccine"/>
			<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H28"/>
			<id>207308</id>
			<summary>
				<section label="Vaccinations" id="28">
					<fragment>In a randomized, placebo-controlled trial of 125 patients with COPD, vaccination reduced the incidence of influenza by 76 percent, regardless of the severity of underlying COPD.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccination"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H29"/>
			<id>207312</id>
			<summary>
				<section label="Rehabilitation" id="29">
					<fragment>Given these benefits, which have been shown to persist for up to 18 months, pulmonary rehabilitation should be considered as an addition to medication therapy for symptomatic patients who have GOLD Stage II, III, or IV COPD.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="medication therapy"/>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H30"/>
			<id>207313</id>
			<summary>
				<section label="Patient education" id="30">
					<fragment>Patient education is an important part of managing patients with COPD and is a routine component of pulmonary rehabilitation.</fragment>
				</section>
			</summary>
			<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H31"/>
			<id>207316</id>
			<summary>
				<section label="Nutrition" id="31">
					<fragment>More than 30 percent of patients with severe COPD have protein-calorie malnutrition.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H31"/>
			<id>207318</id>
			<summary>
				<section label="Nutrition" id="31">
					<fragment>High caloric dietary supplements and megestrol acetate (Megace, an appetite stimulant) have been used in an effort to combat malnutrition.</fragment>
				</section>
			</summary>
			<category term="C0025175" scheme="gov.nih.nlm.semanticType.horm" label="megestrol"/>
			<category term="C0065879" scheme="gov.nih.nlm.semanticType.horm" label="megestrol acetate"/>
			<category term="C0376447" scheme="gov.nih.nlm.semanticType.phsu" label="appetite stimulant"/>
			<category term="C0700004" scheme="gov.nih.nlm.semanticType.horm" label="Megace"/>
			<category term="C1451216" scheme="gov.nih.nlm.semanticType.orch" label="acetate"/>
			<category term="C3536952" scheme="gov.nih.nlm.semanticType.phsu" label="stimulant"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H31"/>
			<id>207321</id>
			<summary>
				<section label="Nutrition" id="31">
					<fragment>Thus, it has been hypothesized that antioxidants may prevent disease progression.</fragment>
				</section>
			</summary>
			<category term="C0003402" scheme="gov.nih.nlm.semanticType.phsu" label="antioxidants"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H31"/>
			<id>207322</id>
			<summary>
				<section label="Nutrition" id="31">
					<fragment>However, controlled clinical trials are needed before antioxidant vitamins can be recommended for the routine management of patients with stable COPD.</fragment>
				</section>
			</summary>
			<category term="C0003402" scheme="gov.nih.nlm.semanticType.phsu" label="antioxidant"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H33"/>
			<id>207324</id>
			<summary>
				<section label="SURGERY" id="33">
					<fragment>Carefully selected patients may benefit from lung volume reduction surgery (LVRS) or lung transplantation.</fragment>
				</section>
			</summary>
			<category term="C0024128" scheme="gov.nih.nlm.semanticType.topp" label="lung transplantation"/>
			<category term="C0375931" scheme="gov.nih.nlm.semanticType.topp" label="lung volume reduction surgery"/>
			<category term="C0519107" scheme="gov.nih.nlm.semanticType.topp" label="lung volume reduction"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H34"/>
			<id>207325</id>
			<summary>
				<section label="Lung volume reduction surgery" id="34">
					<fragment>The National Emphysema Treatment Trial (NETT) enrolled 1218 patients with severe emphysema and compared lung volume reduction surgery (LVRS) to maximal medical therapy.</fragment>
				</section>
			</summary>
			<category term="C0375931" scheme="gov.nih.nlm.semanticType.topp" label="lung volume reduction surgery"/>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="C0519107" scheme="gov.nih.nlm.semanticType.topp" label="lung volume reduction"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H34"/>
			<id>207327</id>
			<summary>
				<section label="Lung volume reduction surgery" id="34">
					<fragment>The efficacy of LVRS varied among patient groups, but there was an overall survival advantage that was most marked in patients with upper lobe emphysema and low exercise capacity.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H35"/>
			<id>207332</id>
			<summary>
				<section label="Transplantation" id="35">
					<fragment>It is important to define disease severity as precisely as possible in order to determine which patients have the most urgent need for lung transplantation and are likely to have the longest survival after transplantation.</fragment>
				</section>
			</summary>
			<category term="C0024128" scheme="gov.nih.nlm.semanticType.topp" label="lung transplantation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H35"/>
			<id>207333</id>
			<summary>
				<section label="Transplantation" id="35">
					<fragment>Guidelines for timing a referral for a transplant evaluation for patients with COPD and emphysema due to alpha-1 antitrypsin deficiency include: BODE index &gt;5.</fragment>
				</section>
			</summary>
			<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="referral"/>
			<category term="C0040732" scheme="gov.nih.nlm.semanticType.topp" label="transplant"/>
			<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207341</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>Opiates may be of benefit for relief of dyspnea in selected patients, such as those with dyspnea unresponsive to the conventional approaches described above.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207342</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>The optimal dose and timing of opiate medication for control of dyspnea in COPD are not known.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207343</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>Forty-eight opiate-naive patients with dyspnea predominantly due to COPD were randomly assigned to oral morphine 20 mg sustained release once daily or placebo for four days.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="morphine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207344</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>Morphine was associated with significant improvements in dyspnea and sleep, although constipation was a substantial adverse effect.</fragment>
				</section>
			</summary>
			<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="Morphine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207345</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>In a separate dose-ranging study among 48 patients, oral sustained release morphine at 10 mg per day provided relief of dyspnea in 19 patients, 20 mg provided relief in another 5, and 30 mg provided relief in 3.</fragment>
				</section>
			</summary>
			<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="morphine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207349</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>Choices include short-acting preparations of morphine, hydromorphone, and oxycodone for chronic, persistent dyspnea and rapid onset agents such as fentanyl buccal or sublingual tablets for episodic dyspnea.</fragment>
				</section>
			</summary>
			<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparations"/>
			<category term="C0012306" scheme="gov.nih.nlm.semanticType.phsu" label="hydromorphone"/>
			<category term="C0015846" scheme="gov.nih.nlm.semanticType.phsu" label="fentanyl"/>
			<category term="C0030049" scheme="gov.nih.nlm.semanticType.phsu" label="oxycodone"/>
			<category term="C0968012" scheme="gov.nih.nlm.semanticType.phsu" label="morphine"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207351</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>Anxiety, depression, and dyspnea are often intertwined and attempts to characterize which symptom is the dominant or primary problem for an individual patient can be difficult.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207352</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>Indeed, hyperventilation from anxiety can often accentuate and occasionally overwhelm patients with dyspnea.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207353</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>Pulmonary rehabilitation can lead to a major improvement in patients with dyspnea, anxiety, and depression and should be strongly considered, especially if the use of opiates is being considered.</fragment>
				</section>
			</summary>
			<category term="C0034991" scheme="gov.nih.nlm.semanticType.topp" label="rehabilitation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207354</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>In addition, psychoactive agents and cognitive behavioral therapy can be helpful in selected patients with anxiety or depression.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive behavioral therapy"/>
			<category term="C0033978" scheme="gov.nih.nlm.semanticType.phsu" label="psychoactive agents"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207355</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>Respiratory stimulants are not beneficial to these patients and can often accentuate dyspnea, even in those with hypercapnic COPD.</fragment>
				</section>
			</summary>
			<category term="C3536778" scheme="gov.nih.nlm.semanticType.phsu" label="Respiratory stimulants"/>
			<category term="C3536952" scheme="gov.nih.nlm.semanticType.phsu" label="stimulants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H19097853"/>
			<id>207356</id>
			<summary>
				<section label="PALLIATIVE TREATMENT OF DYSPNEA" id="19097853">
					<fragment>Patients with advanced COPD may also benefit from hospice care.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H38"/>
			<id>207359</id>
			<summary>
				<section label="Antiproteases" id="38">
					<fragment>Recognition of alpha-1 antitrypsin deficiency as a cause of emphysema increased awareness that an imbalance of various proteases and antiproteases can cause COPD.</fragment>
				</section>
			</summary>
			<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
			<category term="C3540763" scheme="gov.nih.nlm.semanticType.phsu" label="various"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H38"/>
			<id>207360</id>
			<summary>
				<section label="Antiproteases" id="38">
					<fragment>For patients with alpha-1 antitrypsin deficiency, research suggests that infusions of pooled human plasma alpha-1 antitrypsin (so-called augmentation therapy) may slow the rate of disease progression.</fragment>
				</section>
			</summary>
			<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H40"/>
			<id>207377</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="40">
					<fragment>It can be used as a guide for the management of patients with stable COPD.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H40"/>
			<id>207378</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="40">
					<fragment>For all patients with COPD, we recommend that a short-acting bronchodilator (eg, beta-agonist, anticholinergic agent) be prescribed for use as-needed for relief of intermittent increases in dyspnea.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H40"/>
			<id>207380</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="40">
					<fragment>For patients on a long-acting anticholinergic agent, a short-acting beta agonist is generally used for quick relief of COPD symptoms.</fragment>
				</section>
			</summary>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H40"/>
			<id>207381</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="40">
					<fragment>For patients with COPD in whom intermittent short-acting bronchodilators are insufficient to control symptoms or who have other high-risk predictors, including severe or very severe airflow obstruction or two or more exacerbations in the previous year, we recommend adding a regularly scheduled long-acting inhaled bronchodilator.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H40"/>
			<id>207386</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="40">
					<fragment>For patients who continue to have symptoms or have repeated exacerbations despite an optimal long-acting inhaled bronchodilator regimen, we suggest adding an inhaled glucocorticoid.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H40"/>
			<id>207392</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="40">
					<fragment>We recommend long-term oxygen therapy in all patients with COPD who have chronic hypoxemia.</fragment>
				</section>
			</summary>
			<category term="C0184633" scheme="gov.nih.nlm.semanticType.topp" label="oxygen therapy"/>
			<category term="C0418996" scheme="gov.nih.nlm.semanticType.topp" label="long-term oxygen therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H40"/>
			<id>207393</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="40">
					<fragment>All patients with COPD should be advised to quit smoking, educated about COPD, and given a yearly influenza vaccination.</fragment>
				</section>
			</summary>
			<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccination"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H40"/>
			<id>207394</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="40">
					<fragment>In addition, the pneumococcal polysaccharide vaccine should be given to all patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0032594" scheme="gov.nih.nlm.semanticType.phsu" label="polysaccharide"/>
			<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
			<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="pneumococcal"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1447#H40"/>
			<id>207395</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="40">
					<fragment>Patients who continue to have significant symptoms despite the above interventions may be considered for surgical therapy.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Management of acute exacerbations of chronic obstructive pulmonary disease</title>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0308920" scheme="gov.nih.nlm.semanticType.imft" label="ECLIPSE"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C1565734" scheme="gov.nih.nlm.semanticType.phsu" label="ERS"/>
		<category term="C0665990" scheme="gov.nih.nlm.semanticType.phsu" label="eat"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
		<category term="C0011209" scheme="gov.nih.nlm.semanticType.topp" label="delivery"/>
		<category term="C0308779" scheme="gov.nih.nlm.semanticType.phsu" label="deliver"/>
		<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
		<category term="C0001644" scheme="gov.nih.nlm.semanticType.phsu" label="beta adrenergic agonists"/>
		<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0046401" scheme="gov.nih.nlm.semanticType.phsu" label="MDI"/>
		<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0578554" scheme="gov.nih.nlm.semanticType.topp" label="bronchodilator therapies"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0032950" scheme="gov.nih.nlm.semanticType.phsu" label="prednisolone"/>
		<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0025815" scheme="gov.nih.nlm.semanticType.horm" label="methylprednisolone"/>
		<category term="C0001617" scheme="gov.nih.nlm.semanticType.horm" label="Corticosteroids"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="Antibiotics"/>
		<category term="C0001047" scheme="gov.nih.nlm.semanticType.phsu" label="N-acetylcysteine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0002575" scheme="gov.nih.nlm.semanticType.phsu" label="Aminophylline"/>
		<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
		<category term="C1868981" scheme="gov.nih.nlm.semanticType.topp" label="Invasive mechanical ventilation"/>
		<category term="C0086388" scheme="gov.nih.nlm.semanticType.hlca" label="healthcare"/>
		<category term="C0242687" scheme="gov.nih.nlm.semanticType.hlca" label="early intervention"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C1273866" scheme="gov.nih.nlm.semanticType.hlca" label="action plan"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0614162" scheme="gov.nih.nlm.semanticType.orch" label="OH] D"/>
		<category term="C0663764" scheme="gov.nih.nlm.semanticType.orch" label="ng"/>
		<category term="C1957945" scheme="gov.nih.nlm.semanticType.orch" label="OH"/>
		<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
		<category term="C0001644" scheme="gov.nih.nlm.semanticType.phsu" label="beta adrenergic agonist"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="Antibiotics"/>
		<category term="C0088887" scheme="gov.nih.nlm.semanticType.phsu" label="methylxanthines"/>
		<category term="C0454505" scheme="gov.nih.nlm.semanticType.topp" label="sputum clearance"/>
		<category term="C0021778" scheme="gov.nih.nlm.semanticType.topp" label="positive pressure ventilation"/>
		<category term="C3164735" scheme="gov.nih.nlm.semanticType.topp" label="Noninvasive positive pressure ventilation"/>
		<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
		<category term="C1868981" scheme="gov.nih.nlm.semanticType.topp" label="Invasive mechanical ventilation"/>
		<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
		<category term="C1868981" scheme="gov.nih.nlm.semanticType.topp" label="invasive mechanical ventilation"/>
		<id>1461</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H2"/>
			<id>207923</id>
			<summary>
				<section label="PRECIPITANTS" id="2">
					<fragment>It is estimated that 70 to 80 percent of COPD exacerbations are due to respiratory infections.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H2"/>
			<id>207928</id>
			<summary>
				<section label="PRECIPITANTS" id="2">
					<fragment>Among the 550 patients having a COPD exacerbation, the prevalence of pulmonary embolism was 20 percent.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H2"/>
			<id>207930</id>
			<summary>
				<section label="PRECIPITANTS" id="2">
					<fragment>An important limitation of the meta-analysis was its inability to determine whether the pulmonary embolism was the cause of the COPD exacerbation, a result of the COPD exacerbation, or a mere bystander.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H3"/>
			<id>207940</id>
			<summary>
				<section label="RISK FACTORS" id="3">
					<fragment>Gastroesophageal reflux disease (GERD) may be an additional risk factor for COPD exacerbations.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H3"/>
			<id>207942</id>
			<summary>
				<section label="RISK FACTORS" id="3">
					<fragment>A similar observation was made in a case-control study that assessed the presence of GERD symptoms and frequency of COPD exacerbations in 80 patients with COPD.</fragment>
				</section>
			</summary>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H3"/>
			<id>207943</id>
			<summary>
				<section label="RISK FACTORS" id="3">
					<fragment>The presence of GERD symptoms was associated with an increased risk of COPD exacerbations (RR 6.55, 95% CI 1.86 to 23.11).</fragment>
				</section>
			</summary>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H3"/>
			<id>207945</id>
			<summary>
				<section label="RISK FACTORS" id="3">
					<fragment>In a follow-up to the ECLIPSE study, the potential role of pulmonary vascular disease as a risk factor for exacerbations was assessed by using computed tomography scans to compute the ratio of the diameter of the pulmonary artery to the diameter of the aorta (PA:A ratio).</fragment>
				</section>
			</summary>
			<category term="C0308920" scheme="gov.nih.nlm.semanticType.imft" label="ECLIPSE"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H3"/>
			<id>207947</id>
			<summary>
				<section label="RISK FACTORS" id="3">
					<fragment>However, a ratio &gt;1 suggests the presence of pulmonary hypertension, although it does not clarify the cause of pulmonary hypertension (eg, hypoxemia due to COPD or other lung disease, left heart failure, sleep apnea).</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H4"/>
			<id>207953</id>
			<summary>
				<section label="INITIAL EVALUATION" id="4">
					<fragment>Several criteria for hospitalization were proposed in a 2004 position paper from the American Thoracic Society/European Respiratory Society (ATS/ERS): Inadequate response of symptoms to outpatient management.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C1565734" scheme="gov.nih.nlm.semanticType.phsu" label="ERS"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H4"/>
			<id>207955</id>
			<summary>
				<section label="INITIAL EVALUATION" id="4">
					<fragment>Inability to eat or sleep due to symptoms.</fragment>
				</section>
			</summary>
			<category term="C0665990" scheme="gov.nih.nlm.semanticType.phsu" label="eat"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H4"/>
			<id>207966</id>
			<summary>
				<section label="INITIAL EVALUATION" id="4">
					<fragment>A meta-analysis of seven of these trials noted that home care resulted in equivalent clinical outcomes and substantial cost savings compared to hospitalization.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H4"/>
			<id>207968</id>
			<summary>
				<section label="INITIAL EVALUATION" id="4">
					<fragment>Although care at home is feasible in highly selected patients without these characteristics, implementation requires a dedicated support team to conduct ongoing clinical assessments and provide home care.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H6"/>
			<id>207973</id>
			<summary>
				<section label="TREATMENT GOALS" id="6">
					<fragment>Optimizing lung function by administering bronchodilators and other pharmacologic agents.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H7"/>
			<id>207981</id>
			<summary>
				<section label="OXYGEN THERAPY" id="7">
					<fragment>There are numerous devices available to deliver supplemental oxygen during an acute exacerbation of COPD: Venturi masks are the preferred means of oxygen delivery because they permit a precise delivered fraction of inspired oxygen (FiO2. Venturi masks can deliver an FiO 2 of 24, 28, 31, 35, 40, or 60 percent. Nasal cannulae can provide flow rates up to 6 L per minute with an associated FiO2 of approximately 40 percent. They are more comfortable and convenient for the patient, especially during oral feedings. When higher inspired concentrations of oxygen are needed, simple facemasks can provide an FiO2 up to 55 percent using flow rates of 6 to 10 L per minute. However, variations in minute ventilation and inconsistent entrainment of room air affect the FiO2 when simple facemasks (or nasal cannulae) are used.</fragment>
				</section>
			</summary>
			<category term="C0011209" scheme="gov.nih.nlm.semanticType.topp" label="delivery"/>
			<category term="C0308779" scheme="gov.nih.nlm.semanticType.phsu" label="deliver"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H7"/>
			<id>207984</id>
			<summary>
				<section label="OXYGEN THERAPY" id="7">
					<fragment>Inability to correct hypoxemia with a relatively low FiO2 (eg, 4 L/min by nasal cannula or 35 percent by mask) should prompt consideration of pulmonary emboli, acute respiratory distress syndrome, pulmonary edema, or severe pneumonia as the cause of respiratory failure.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H7"/>
			<id>207986</id>
			<summary>
				<section label="OXYGEN THERAPY" id="7">
					<fragment>Hypercapnia is generally well tolerated in patients whose arterial carbon dioxide tension (PaCO2) is chronically elevated.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H9"/>
			<id>207989</id>
			<summary>
				<section label="Beta adrenergic agonists" id="9">
					<fragment>Inhaled short-acting beta adrenergic agonists (eg, albuterol) are the mainstay of therapy for an acute exacerbation of COPD because of their rapid onset of action and efficacy in producing bronchodilation.</fragment>
				</section>
			</summary>
			<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
			<category term="C0001644" scheme="gov.nih.nlm.semanticType.phsu" label="beta adrenergic agonists"/>
			<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H9"/>
			<id>207992</id>
			<summary>
				<section label="Beta adrenergic agonists" id="9">
					<fragment>We favor nebulized therapy because many patients with COPD have difficulty using proper MDI technique in the setting of an acute exacerbation.</fragment>
				</section>
			</summary>
			<category term="C0046401" scheme="gov.nih.nlm.semanticType.phsu" label="MDI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H9"/>
			<id>207994</id>
			<summary>
				<section label="Beta adrenergic agonists" id="9">
					<fragment>Increasing the dose of nebulized albuterol to 5 mg does not have a significant impact on spirometry or clinical outcomes.</fragment>
				</section>
			</summary>
			<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H9"/>
			<id>207996</id>
			<summary>
				<section label="Beta adrenergic agonists" id="9">
					<fragment>Patients with severe COPD are at risk for hypercapnia with administration of supplemental oxygen, so concern has been raised about the risk of hypercapnia during bronchodilator treatments using oxygen-driven nebulizers.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H9"/>
			<id>207999</id>
			<summary>
				<section label="Beta adrenergic agonists" id="9">
					<fragment>Parenteral use of these agents results in greater inotropic and chronotropic effects, which may cause arrhythmias or myocardial ischemia in susceptible individuals.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H10"/>
			<id>208001</id>
			<summary>
				<section label="Anticholinergic agents" id="10">
					<fragment>This is based on several studies that found that combination therapy produces bronchodilation in excess of that achieved by either agent alone in patients with a COPD exacerbation, an asthma exacerbation, or stable COPD.</fragment>
				</section>
			</summary>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H344158021"/>
			<id>208005</id>
			<summary>
				<section label="Efficacy" id="344158021">
					<fragment>Systemic glucocorticoids, when added to the bronchodilator therapies described above, improve symptoms and lung function, and decrease the length of hospital stay.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0578554" scheme="gov.nih.nlm.semanticType.topp" label="bronchodilator therapies"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H344158021"/>
			<id>208006</id>
			<summary>
				<section label="Efficacy" id="344158021">
					<fragment>This was illustrated by a trial that randomly assigned 271 patients with a COPD exacerbation to receive either systemic glucocorticoids or placebo for up to two weeks.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H344158046"/>
			<id>208009</id>
			<summary>
				<section label="Route" id="344158046">
					<fragment>As an example, a randomized trial assigned 210 patients hospitalized with a COPD exacerbation to receive oral or intravenous prednisolone (60 mg daily) for five days and found no difference between the two groups in the rate of treatment failure, length of hospital stay, improvement in spirometry, or improvement in quality of life.</fragment>
				</section>
			</summary>
			<category term="C0032950" scheme="gov.nih.nlm.semanticType.phsu" label="prednisolone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H344158046"/>
			<id>208010</id>
			<summary>
				<section label="Route" id="344158046">
					<fragment>However, intravenous glucocorticoids are typically administered to patients who present with a severe exacerbation, who respond poorly to oral glucocorticoids, who are unable to take oral medication, or who may have impaired absorption due to decreased splanchnic perfusion (eg, patients in shock).</fragment>
				</section>
			</summary>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H344158097"/>
			<id>208019</id>
			<summary>
				<section label="Dose" id="344158097">
					<fragment>As this was an observational study and did not include objective measures of airflow limitation, it is possible that less ill patients were more likely to receive oral treatment.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H344158097"/>
			<id>208021</id>
			<summary>
				<section label="Dose" id="344158097">
					<fragment>For patients with impending or actual acute respiratory failure due to a COPD exacerbation, most clinicians would use an intravenous formulation at a higher dose, such as the equivalent of methylprednisolone 60 mg intravenously, one to four times daily, although outcomes data to guide this practice are not available.</fragment>
				</section>
			</summary>
			<category term="C0025815" scheme="gov.nih.nlm.semanticType.horm" label="methylprednisolone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H344158053"/>
			<id>208029</id>
			<summary>
				<section label="Duration" id="344158053">
					<fragment>A trial performed subsequent to the systematic review, the Reduction in the Use of Corticosteroids in Exacerbated COPD (REDUCE) trial, randomly assigned 314 patients with acute exacerbations of COPD, of whom 289 required hospitalization, to prednisone 40 mg daily for 5 or 14 days.</fragment>
				</section>
			</summary>
			<category term="C0001617" scheme="gov.nih.nlm.semanticType.horm" label="Corticosteroids"/>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H12"/>
			<id>208036</id>
			<summary>
				<section label="Antibiotics" id="12">
					<fragment>Antibiotics are indicated for many patients having a COPD exacerbation.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="Antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H13"/>
			<id>208040</id>
			<summary>
				<section label="Mucoactive agents" id="13">
					<fragment>The lack of efficacy of mucoactive agents in the treatment of COPD exacerbations was best demonstrated by a double-blind trial that randomly assigned 50 patients with a COPD exacerbation to receive N-acetylcysteine (600 mg, twice daily) or placebo for seven days.</fragment>
				</section>
			</summary>
			<category term="C0001047" scheme="gov.nih.nlm.semanticType.phsu" label="N-acetylcysteine"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H14"/>
			<id>208042</id>
			<summary>
				<section label="Methylxanthines" id="14">
					<fragment>Aminophylline and theophylline are NOT recommended for the treatment of acute exacerbations of COPD.</fragment>
				</section>
			</summary>
			<category term="C0002575" scheme="gov.nih.nlm.semanticType.phsu" label="Aminophylline"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H17"/>
			<id>208048</id>
			<summary>
				<section label="Noninvasive ventilation" id="17">
					<fragment>It improves numerous clinical outcomes and is the preferred method of ventilatory support in many patients with an acute exacerbation of COPD.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H17"/>
			<id>208049</id>
			<summary>
				<section label="Noninvasive ventilation" id="17">
					<fragment>Optimal initial settings for NPPV have not been established.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H18"/>
			<id>208054</id>
			<summary>
				<section label="Invasive ventilation" id="18">
					<fragment>Invasive mechanical ventilation for acute respiratory failure due to a COPD exacerbation is discussed separately.</fragment>
				</section>
			</summary>
			<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
			<category term="C1868981" scheme="gov.nih.nlm.semanticType.topp" label="Invasive mechanical ventilation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H19"/>
			<id>208057</id>
			<summary>
				<section label="PROGNOSIS" id="19">
					<fragment>Among 1016 patients with an acute exacerbation of COPD and a PaCO2 of 50 mmHg or more, the 6 and 12 month mortality rates were 33 and 43 percent, respectively.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H19"/>
			<id>208058</id>
			<summary>
				<section label="PROGNOSIS" id="19">
					<fragment>In a study of 260 patients admitted with a COPD exacerbation, the one year mortality was 28 percent.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H20"/>
			<id>208065</id>
			<summary>
				<section label="PREVENTION" id="20">
					<fragment>An action plan encourages early intervention by giving patients guidelines on how to recognize an exacerbation, how to change their medication regimen accordingly, and when to contact their healthcare provider.</fragment>
				</section>
			</summary>
			<category term="C0086388" scheme="gov.nih.nlm.semanticType.hlca" label="healthcare"/>
			<category term="C0242687" scheme="gov.nih.nlm.semanticType.hlca" label="early intervention"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C1273866" scheme="gov.nih.nlm.semanticType.hlca" label="action plan"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H20"/>
			<id>208068</id>
			<summary>
				<section label="PREVENTION" id="20">
					<fragment>The effect of high dose vitamin D supplementation on the incidence of COPD exacerbations was assessed in patients with moderate or more severe COPD who were randomly assigned to take vitamin D 100,000 IU or placebo orally every four weeks for a year.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H20"/>
			<id>208070</id>
			<summary>
				<section label="PREVENTION" id="20">
					<fragment>However, patients with severe vitamin D deficiency (serum 25-[OH] D levels &lt;10 ng/mL) at baseline had a significant reduction in exacerbations.</fragment>
				</section>
			</summary>
			<category term="C0614162" scheme="gov.nih.nlm.semanticType.orch" label="OH] D"/>
			<category term="C0663764" scheme="gov.nih.nlm.semanticType.orch" label="ng"/>
			<category term="C1957945" scheme="gov.nih.nlm.semanticType.orch" label="OH"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H22"/>
			<id>208084</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>An acute exacerbation of COPD is characterized by an acute increase in symptoms beyond normal day-to-day variation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H22"/>
			<id>208085</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>We recommend that all patients having a COPD exacerbation receive both an inhaled short-acting beta adrenergic agonist and an inhaled short-acting anticholinergic agent, rather than either medication alone.</fragment>
				</section>
			</summary>
			<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
			<category term="C0001644" scheme="gov.nih.nlm.semanticType.phsu" label="beta adrenergic agonist"/>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H22"/>
			<id>208086</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>We recommend that all patients having a COPD exacerbation receive systemic glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H22"/>
			<id>208088</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>Antibiotics are indicated for many patients having a COPD exacerbation.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="Antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H22"/>
			<id>208089</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>Mucoactive agents, mechanical techniques to augment sputum clearance, and methylxanthines have not been shown to confer benefit for patients with a COPD exacerbation.</fragment>
				</section>
			</summary>
			<category term="C0088887" scheme="gov.nih.nlm.semanticType.phsu" label="methylxanthines"/>
			<category term="C0454505" scheme="gov.nih.nlm.semanticType.topp" label="sputum clearance"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H22"/>
			<id>208090</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>We suggest that all patients who are hypoxemic be given supplemental oxygen targeting a PaO2 of 60 to 70 mmHg, with an oxyhemoglobin saturation of 90 to 94 percent.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H22"/>
			<id>208091</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>Noninvasive positive pressure ventilation (NPPV) improves numerous clinical outcomes and is the preferred method of ventilatory support in many patients with an acute exacerbation of COPD.</fragment>
				</section>
			</summary>
			<category term="C0021778" scheme="gov.nih.nlm.semanticType.topp" label="positive pressure ventilation"/>
			<category term="C3164735" scheme="gov.nih.nlm.semanticType.topp" label="Noninvasive positive pressure ventilation"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H22"/>
			<id>208092</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>Invasive mechanical ventilation is required in patients with respiratory failure who fail NPPV, do not tolerate NPPV, or have contraindications to NPPV.</fragment>
				</section>
			</summary>
			<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
			<category term="C1868981" scheme="gov.nih.nlm.semanticType.topp" label="Invasive mechanical ventilation"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1461#H22"/>
			<id>208093</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>Both NPPV and invasive mechanical ventilation for patients with an acute exacerbation of COPD are discussed separately.</fragment>
				</section>
			</summary>
			<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
			<category term="C1868981" scheme="gov.nih.nlm.semanticType.topp" label="invasive mechanical ventilation"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Management of infection in acute exacerbations of chronic obstructive pulmonary disease</title>
		<category term="C0623757" scheme="gov.nih.nlm.semanticType.orch" label="PCR"/>
		<category term="C0020674" scheme="gov.nih.nlm.semanticType.topp" label="induction"/>
		<category term="C0079189" scheme="gov.nih.nlm.semanticType.imft" label="cytokines"/>
		<category term="C0282554" scheme="gov.nih.nlm.semanticType.imft" label="chemokines"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C1962990" scheme="gov.nih.nlm.semanticType.imft" label="Pseudomonas aeruginosa"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0653863" scheme="gov.nih.nlm.semanticType.phsu" label="indicator"/>
		<category term="C0659306" scheme="gov.nih.nlm.semanticType.orch" label="toxins"/>
		<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
		<category term="C3536753" scheme="gov.nih.nlm.semanticType.horm" label="calcitonin"/>
		<category term="C0279516" scheme="gov.nih.nlm.semanticType.antb" label="antibacterial"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0150600" scheme="gov.nih.nlm.semanticType.hlca" label="guidance"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0657532" scheme="gov.nih.nlm.semanticType.aapp" label="C-reactive protein"/>
		<category term="C0657532" scheme="gov.nih.nlm.semanticType.aapp" label="CRP"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="Antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="Antibiotic"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
		<category term="C1997883" scheme="gov.nih.nlm.semanticType.topp" label="ventilation (noninvasive"/>
		<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0554804" scheme="gov.nih.nlm.semanticType.topp" label="ventilatory assistance"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C1440658" scheme="gov.nih.nlm.semanticType.imft" label="Haemophilus influenzae"/>
		<category term="C1962990" scheme="gov.nih.nlm.semanticType.imft" label="Pseudomonas aeruginosa"/>
		<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0304320" scheme="gov.nih.nlm.semanticType.antb" label="third-generation cephalosporin"/>
		<category term="C0949665" scheme="gov.nih.nlm.semanticType.phsu" label="fluoroquinolone"/>
		<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporin"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003240" scheme="gov.nih.nlm.semanticType.antb" label="macrolides"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0949665" scheme="gov.nih.nlm.semanticType.phsu" label="fluoroquinolones"/>
		<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
		<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
		<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
		<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0060400" scheme="gov.nih.nlm.semanticType.antb" label="cefixime"/>
		<category term="C0949665" scheme="gov.nih.nlm.semanticType.phsu" label="fluoroquinolones"/>
		<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0003451" scheme="gov.nih.nlm.semanticType.phsu" label="antiviral"/>
		<category term="C0280274" scheme="gov.nih.nlm.semanticType.topp" label="antiviral therapy"/>
		<category term="C0021403" scheme="gov.nih.nlm.semanticType.imft" label="influenza vaccine"/>
		<category term="C0032594" scheme="gov.nih.nlm.semanticType.phsu" label="polysaccharide"/>
		<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccination"/>
		<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
		<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="pneumococcal"/>
		<category term="C0857515" scheme="gov.nih.nlm.semanticType.topp" label="booster"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="pneumococcal"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
		<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccination"/>
		<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
		<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="pneumococcal"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
		<category term="C0184666" scheme="gov.nih.nlm.semanticType.hlca" label="hospital admissions"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="prophylactic antibiotic therapy"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003240" scheme="gov.nih.nlm.semanticType.antb" label="macrolide"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C1268823" scheme="gov.nih.nlm.semanticType.phsu" label="prophylactic agent"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="Antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="Antibiotic"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
		<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
		<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
		<id>7019</id>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H3"/>
			<id>211757</id>
			<summary>
				<section label="Viral infection" id="3">
					<fragment>The most common viruses associated with exacerbations of COPD are rhinoviruses.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H3"/>
			<id>211760</id>
			<summary>
				<section label="Viral infection" id="3">
					<fragment>Identification of a virus in the sputum sample of a patient having a COPD exacerbation is relatively common and does not necessarily mean that this is the cause of the exacerbation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H3"/>
			<id>211761</id>
			<summary>
				<section label="Viral infection" id="3">
					<fragment>In fact, such viruses have been found in up to 15 percent of asymptomatic individuals with stable COPD using sensitive PCR-based assays.</fragment>
				</section>
			</summary>
			<category term="C0623757" scheme="gov.nih.nlm.semanticType.orch" label="PCR"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H3"/>
			<id>211764</id>
			<summary>
				<section label="Viral infection" id="3">
					<fragment>Viral infection of the airway epithelial cells induces inflammation.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H3"/>
			<id>211765</id>
			<summary>
				<section label="Viral infection" id="3">
					<fragment>This causes airway epithelial damage, muscarinic receptor stimulation, and induction of inflammatory mediators (eg, cytokines, chemokines).</fragment>
				</section>
			</summary>
			<category term="C0020674" scheme="gov.nih.nlm.semanticType.topp" label="induction"/>
			<category term="C0079189" scheme="gov.nih.nlm.semanticType.imft" label="cytokines"/>
			<category term="C0282554" scheme="gov.nih.nlm.semanticType.imft" label="chemokines"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H3"/>
			<id>211766</id>
			<summary>
				<section label="Viral infection" id="3">
					<fragment>Airway eosinophilia is associated with viral mediated exacerbations, which highlights the importance of the host response to infection and its impact on both inflammation and symptoms.</fragment>
				</section>
			</summary>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H4"/>
			<id>211769</id>
			<summary>
				<section label="Bacterial infection" id="4">
					<fragment>Pseudomonas aeruginosa and Enterobacteriaceae are also commonly isolated, particularly from patients with severe COPD.</fragment>
				</section>
			</summary>
			<category term="C1962990" scheme="gov.nih.nlm.semanticType.imft" label="Pseudomonas aeruginosa"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H4"/>
			<id>211772</id>
			<summary>
				<section label="Bacterial infection" id="4">
					<fragment>This hypothesis is supported by the following observations: Exacerbations with new bacterial strains are more likely to be associated with a humoral immune response - In one study, exacerbations with a new strain of H. influenzae were significantly more likely to be associated with a humoral immune response than exacerbations with preexisting strains of H. influenzae (61 versus 21 percent).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H4"/>
			<id>211775</id>
			<summary>
				<section label="Bacterial infection" id="4">
					<fragment>Exacerbations with new bacterial strains are associated with a more robust inflammatory response - Exacerbations of COPD with a new strain of bacteria have been associated with more intense neutrophilic airway inflammation and systemic inflammation than exacerbations not associated with a change in preexisting bacterial strains or recovery of pathogenic bacteria.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H4"/>
			<id>211777</id>
			<summary>
				<section label="Bacterial infection" id="4">
					<fragment>In an animal model, new strains of H. influenzae that were known to be associated with COPD exacerbation caused significantly more airway neutrophil recruitment than colonizing strains of H. influenzae.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H4"/>
			<id>211778</id>
			<summary>
				<section label="Bacterial infection" id="4">
					<fragment>Most of the human studies were performed in patients with COPD who had chronic bronchitis because expectorated sputum could be obtained easily.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H4"/>
			<id>211779</id>
			<summary>
				<section label="Bacterial infection" id="4">
					<fragment>Thus, the degree to which the data can be generalized to exacerbations in patients with COPD who do not have chronic bronchitis is unknown.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H5"/>
			<id>211783</id>
			<summary>
				<section label="Atypical bacteria" id="5">
					<fragment>There are conflicting data regarding the incidence of atypical bacterial infection in patients having an exacerbation of COPD.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H5"/>
			<id>211785</id>
			<summary>
				<section label="Atypical bacteria" id="5">
					<fragment>The incidence of Chlamydophila pneumoniae in exacerbations of COPD appears to be 3 to 5 percent (Mycoplasma pneumoniae and Legionella spp are even more rare) if one considers only studies using rigorous methodology that excluded pneumonia and defined infection as a strict fourfold increase in titer or a positive culture.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H6"/>
			<id>211786</id>
			<summary>
				<section label="Coinfection" id="6">
					<fragment>Coinfection is increasingly being considered in studies looking at the pathogenesis of COPD exacerbation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H6"/>
			<id>211787</id>
			<summary>
				<section label="Coinfection" id="6">
					<fragment>Such studies categorize exacerbations of COPD due to respiratory infection as being caused by viral infection alone, bacterial infection alone, or both.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H6"/>
			<id>211791</id>
			<summary>
				<section label="Coinfection" id="6">
					<fragment>In a similar study of outpatients, coinfection was associated with more symptoms, a larger fall in the forced expiratory volume in one second (FEV1), higher bacterial loads, and systemic inflammation.</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H8"/>
			<id>211795</id>
			<summary>
				<section label="Sputum Gram stain and culture" id="8">
					<fragment>Sputum Gram stain and cultures are often not useful for identifying bacterial infection in patients with COPD exacerbations for the following reasons: Gram stain and culture of expectorated sputum are similar during exacerbations and stable disease.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H8"/>
			<id>211799</id>
			<summary>
				<section label="Sputum Gram stain and culture" id="8">
					<fragment>In one study that collected sequential sputum cultures from patients with stable COPD, molecular typing revealed that apparently identical bacterial strains of H. influenzae were intermittently recovered, suggesting that false-negative culture results were common.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H8"/>
			<id>211803</id>
			<summary>
				<section label="Sputum Gram stain and culture" id="8">
					<fragment>A possible exception recognized by the GOLD guidelines is that sputum cultures may be helpful in patients who are strongly suspected of having a bacterial infection, but fail to respond to initial antibiotic therapy.</fragment>
				</section>
			</summary>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H9"/>
			<id>211807</id>
			<summary>
				<section label="Risk factors for Pseudomonas" id="9">
					<fragment>In contrast to H. influenzae, M. catarrhalis, and S. pneumoniae, Pseudomonas spp can easily be recovered from expectorated sputum obtained before initiating therapy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H10"/>
			<id>211809</id>
			<summary>
				<section label="Sputum purulence" id="10">
					<fragment>Sputum purulence may be a marker of bacterial infection during an exacerbation of COPD.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H10"/>
			<id>211810</id>
			<summary>
				<section label="Sputum purulence" id="10">
					<fragment>In one bronchoscopic study of 40 patients with COPD exacerbations, more patients with purulent sputum had bronchial infection than patients with mucoid sputum (77 versus 6 percent).</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H10"/>
			<id>211812</id>
			<summary>
				<section label="Sputum purulence" id="10">
					<fragment>Based on these observations, we believe that sputum purulence is an important, but not absolute, indicator of bacterial infection in patients with an exacerbation of COPD.</fragment>
				</section>
			</summary>
			<category term="C0653863" scheme="gov.nih.nlm.semanticType.phsu" label="indicator"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H106397380"/>
			<id>211813</id>
			<summary>
				<section label="reactive protein" id="106397380">
					<fragment>Procalcitonin is a peptide precursor of calcitonin that is released by parenchymal cells in response to bacterial toxins, leading to elevated serum levels in patients with bacterial infections;</fragment>
				</section>
			</summary>
			<category term="C0659306" scheme="gov.nih.nlm.semanticType.orch" label="toxins"/>
			<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
			<category term="C3536753" scheme="gov.nih.nlm.semanticType.horm" label="calcitonin"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H106397380"/>
			<id>211814</id>
			<summary>
				<section label="reactive protein" id="106397380">
					<fragment>in contrast, procalcitonin is down-regulated in patients with viral infections.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H106397380"/>
			<id>211815</id>
			<summary>
				<section label="reactive protein" id="106397380">
					<fragment>Procalcitonin has been evaluated to facilitate the decision of whether to use antibacterial agents in patients with acute respiratory tract infections and when antibiotics can be safely stopped.</fragment>
				</section>
			</summary>
			<category term="C0279516" scheme="gov.nih.nlm.semanticType.antb" label="antibacterial"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H106397380"/>
			<id>211816</id>
			<summary>
				<section label="reactive protein" id="106397380">
					<fragment>In a 2012 Cochrane meta-analysis, procalcitonin guidance for antibiotic use was associated with a reduction in antibiotic exposure without an increase in mortality or treatment failure in any clinical setting (eg, outpatient clinic, emergency department) or in patients with any type of acute respiratory infection, including COPD exacerbation.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0150600" scheme="gov.nih.nlm.semanticType.hlca" label="guidance"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H106397380"/>
			<id>211817</id>
			<summary>
				<section label="reactive protein" id="106397380">
					<fragment>In a study of patients with acute exacerbations of COPD, procalcitonin showed poor concordance with sputum purulence, whereas another biomarker, C-reactive protein (CRP), correlated with sputum purulence.</fragment>
				</section>
			</summary>
			<category term="C0657532" scheme="gov.nih.nlm.semanticType.aapp" label="C-reactive protein"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H106397380"/>
			<id>211819</id>
			<summary>
				<section label="reactive protein" id="106397380">
					<fragment>Studies of procalcitonin and CRP in patients with community-acquired pneumonia are presented separately.</fragment>
				</section>
			</summary>
			<category term="C0657532" scheme="gov.nih.nlm.semanticType.aapp" label="CRP"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H12"/>
			<id>211821</id>
			<summary>
				<section label="Rationale" id="12">
					<fragment>The use of antibiotics in exacerbations of COPD is based on placebo-controlled trials and retrospective population studies that found that antibiotics improve clinical outcomes in many patients having an exacerbation of COPD.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310400"/>
			<id>211826</id>
			<summary>
				<section label="Hospitalized patients" id="258310400">
					<fragment>High-quality evidence from only the single trial described above showed a mortality benefit in critically ill patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310400"/>
			<id>211828</id>
			<summary>
				<section label="Hospitalized patients" id="258310400">
					<fragment>In the multivariate analysis of a retrospective cohort study that included 84,621 patients who were hospitalized patients with acute exacerbations of COPD, the risk of treatment failure was lower in those who received antibiotics during the first two hospital days compared with those who were treated later or not at all (odds ratio [OR] 0.87, 95% CI 0.82-0.92);</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310400"/>
			<id>211829</id>
			<summary>
				<section label="Hospitalized patients" id="258310400">
					<fragment>treatment failure was a composite endpoint defined as the initiation of mechanical ventilation after the second hospital day, inpatient mortality, or readmission for acute exacerbations of COPD within 30 days of discharge.</fragment>
				</section>
			</summary>
			<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310400"/>
			<id>211831</id>
			<summary>
				<section label="Hospitalized patients" id="258310400">
					<fragment>Another study examined whether there is additive benefit of antibiotics over that provided by systemic glucocorticoids in the treatment of moderate to severe exacerbations in hospitalized patients not requiring mechanical ventilation.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310400"/>
			<id>211835</id>
			<summary>
				<section label="Hospitalized patients" id="258310400">
					<fragment>This may explain the substantial clinical failure rate of 39 percent at 30 days, even when patients received both antibiotics and glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310400"/>
			<id>211837</id>
			<summary>
				<section label="Hospitalized patients" id="258310400">
					<fragment>A non-randomized prospective study was conducted in 73 patients with COPD exacerbations admitted to the hospital.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310400"/>
			<id>211838</id>
			<summary>
				<section label="Hospitalized patients" id="258310400">
					<fragment>If patients had purulent sputum, they received antibiotics;</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310400"/>
			<id>211840</id>
			<summary>
				<section label="Hospitalized patients" id="258310400">
					<fragment>Clinical outcomes were similar in the two groups.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310400"/>
			<id>211842</id>
			<summary>
				<section label="Hospitalized patients" id="258310400">
					<fragment>Whether antibiotics can be safely withheld from patients with acute exacerbations of COPD admitted to the hospital who do not have purulent sputum is an important question that needs to be addressed in a randomized trial.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310507"/>
			<id>211843</id>
			<summary>
				<section label="Outpatients" id="258310507">
					<fragment>The efficacy of antibiotics for COPD exacerbations is less well-established for outpatients than for inpatients.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310507"/>
			<id>211846</id>
			<summary>
				<section label="Outpatients" id="258310507">
					<fragment>Antibiotic therapy increased the likelihood of clinical improvement, defined as resolution of symptoms without additional intervention (68 versus 55 percent with placebo).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="Antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="Antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310507"/>
			<id>211848</id>
			<summary>
				<section label="Outpatients" id="258310507">
					<fragment>A randomized trial showed that amoxicillin-clavulanate administration for COPD exacerbations demonstrated both short- and long-term benefits in outpatients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310507"/>
			<id>211850</id>
			<summary>
				<section label="Outpatients" id="258310507">
					<fragment>Median time to the next exacerbation was 233 days with amoxicillin-clavulanate compared to 166 days with placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310507"/>
			<id>211851</id>
			<summary>
				<section label="Outpatients" id="258310507">
					<fragment>A population-based cohort study evaluated the risk of subsequent COPD exacerbations among nearly 19,000 outpatients treated for an exacerbation with oral glucocorticoids with or without antibiotics.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310507"/>
			<id>211852</id>
			<summary>
				<section label="Outpatients" id="258310507">
					<fragment>Median time to the second exacerbation was significantly longer among patients who received antibiotics plus oral glucocorticoids compared with those who received oral glucocorticoids alone (418 versus 321 days);</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310507"/>
			<id>211854</id>
			<summary>
				<section label="Outpatients" id="258310507">
					<fragment>Mortality during follow-up was also lower in patients who received antibiotics (hazard ratio 0.82, 99% CI 0.66-0.98).</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H258310507"/>
			<id>211858</id>
			<summary>
				<section label="Outpatients" id="258310507">
					<fragment>Clinical failure rates with moxifloxacin and amoxicillin-clavulanate were similar (21 versus 22 percent, respectively), demonstrating that both antibiotics are good choices outpatients with COPD exacerbations.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H13"/>
			<id>211860</id>
			<summary>
				<section label="Indications" id="13">
					<fragment>To try to maximize the benefit of antibiotic therapy, many clinical practice guidelines recommend antibiotic therapy only for those patients who are most likely to have bacterial infection or are most ill.</fragment>
				</section>
			</summary>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H13"/>
			<id>211861</id>
			<summary>
				<section label="Indications" id="13">
					<fragment>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, which are broader than the original Anthonisen criteria, recommend antibiotic therapy for patients who have the following features: a severe exacerbation requiring mechanical ventilation (noninvasive or invasive) or an exacerbation with increased sputum purulence plus either increased dyspnea or increased sputum volume.</fragment>
				</section>
			</summary>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
			<category term="C1997883" scheme="gov.nih.nlm.semanticType.topp" label="ventilation (noninvasive"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H13"/>
			<id>211862</id>
			<summary>
				<section label="Indications" id="13">
					<fragment>We vary slightly from the GOLD guidelines in our clinical practices: We recommend antibiotics in patients with a moderate to severe COPD exacerbation, which is defined as having at least two of these three symptoms - increased dyspnea, increased sputum volume, or increased sputum purulence - or requiring hospitalization.</fragment>
				</section>
			</summary>
			<category term="C0018033" scheme="gov.nih.nlm.semanticType.phsu" label="GOLD"/>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H13"/>
			<id>211863</id>
			<summary>
				<section label="Indications" id="13">
					<fragment>We do not initiate antibiotic therapy in patients whose exacerbation is mild, which we define as having only one of these three symptoms and not requiring hospitalization or ventilatory assistance (either invasive or noninvasive).</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0554804" scheme="gov.nih.nlm.semanticType.topp" label="ventilatory assistance"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211864</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>The optimal antibiotic regimen for the treatment of exacerbations of COPD has not been determined.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211866</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>Specifically, we prescribe a broader antibiotic regimen for patients who have risk factors for a poor outcome.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211868</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>This approach is illustrated in separate algorithms for selection of antibiotics in outpatients ) and inpatients.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211871</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>However, this approach has not been shown in prospective controlled trials to improve clinical outcomes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211872</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>The initial antibiotic regimen should target likely bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in most patients) and take into account local patterns of antibiotic resistance.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="C1440658" scheme="gov.nih.nlm.semanticType.imft" label="Haemophilus influenzae"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211873</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>Pseudomonas aeruginosa and Enterobacteriaceae can occur in patients with severe COPD.</fragment>
				</section>
			</summary>
			<category term="C1962990" scheme="gov.nih.nlm.semanticType.imft" label="Pseudomonas aeruginosa"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211874</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>Risk factors for P. aeruginosa infection are described above.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211876</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>However, amoxicillin is no longer considered a first-line agent because it is inactive against most nontypeable H. influenzae and M. catarrhalis.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211877</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>Other (ie, second-line) antibiotics are also logical choices for outpatients based upon in vitro activity and trials showing efficacy that is comparable, but usually not superior, to doxycycline and trimethoprim-sulfamethoxazole.</fragment>
				</section>
			</summary>
			<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211879</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>In patients with complicated COPD and risk factors for Pseudomonas who do not have indications for hospitalization, we suggest ciprofloxacin.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211880</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>The majority of patients with COPD exacerbations are treated as outpatients.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H14"/>
			<id>211884</id>
			<summary>
				<section label="Choice of antibiotic" id="14">
					<fragment>Hospitalized patients without risk factors for Pseudomonas can be treated with a respiratory fluoroquinolone (levofloxacin, moxifloxacin) or a third-generation cephalosporin (ceftriaxone or cefotaxime).</fragment>
				</section>
			</summary>
			<category term="C0304320" scheme="gov.nih.nlm.semanticType.antb" label="third-generation cephalosporin"/>
			<category term="C0949665" scheme="gov.nih.nlm.semanticType.phsu" label="fluoroquinolone"/>
			<category term="C3536856" scheme="gov.nih.nlm.semanticType.antb" label="cephalosporin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H15"/>
			<id>211888</id>
			<summary>
				<section label="Comparisons" id="15">
					<fragment>Second-line antibiotics were significantly more likely than first-line antibiotics to achieve treatment success, defined as resolution or improvement of symptoms (OR 0.51, 95% CI 0.34-0.75).</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H15"/>
			<id>211891</id>
			<summary>
				<section label="Comparisons" id="15">
					<fragment>A meta-analysis of 19 randomized trials (7405 patients with exacerbations of COPD) compared the effectiveness of macrolides, fluoroquinolones, and amoxicillin-clavulanate.</fragment>
				</section>
			</summary>
			<category term="C0003240" scheme="gov.nih.nlm.semanticType.antb" label="macrolides"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0949665" scheme="gov.nih.nlm.semanticType.phsu" label="fluoroquinolones"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H15"/>
			<id>211896</id>
			<summary>
				<section label="Comparisons" id="15">
					<fragment>In a randomized trial that included 170 patients with acute exacerbations of COPD requiring mechanical ventilation, patients received a 10 day course of either trimethoprim-sulfamethoxazole or ciprofloxacin.</fragment>
				</section>
			</summary>
			<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
			<category term="C1542215" scheme="gov.nih.nlm.semanticType.topp" label="mechanical ventilation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H15"/>
			<id>211897</id>
			<summary>
				<section label="Comparisons" id="15">
					<fragment>Hospital mortality and the need for additional antibiotic prescriptions were similar in both groups, indicating that trimethoprim-sulfamethoxazole was non-inferior to ciprofloxacin.</fragment>
				</section>
			</summary>
			<category term="C0041041" scheme="gov.nih.nlm.semanticType.antb" label="trimethoprim"/>
			<category term="C0041044" scheme="gov.nih.nlm.semanticType.phsu" label="trimethoprim-sulfamethoxazole"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H15"/>
			<id>211901</id>
			<summary>
				<section label="Comparisons" id="15">
					<fragment>For these reasons, we do not recommend either regimen for patients with severe COPD exacerbations requiring hospitalization.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H16"/>
			<id>211902</id>
			<summary>
				<section label="Duration" id="16">
					<fragment>The duration of antibiotic therapy for patients with a COPD exacerbation is usually three to seven days, depending upon the response to therapy.</fragment>
				</section>
			</summary>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H16"/>
			<id>211903</id>
			<summary>
				<section label="Duration" id="16">
					<fragment>A meta-analysis that compared five days to seven or more days of antimicrobial therapy (fluoroquinolones, cefixime, or clarithromycin) for exacerbations of COPD found no difference in outcome between the two groups, although there were fewer adverse events among patients who received a five-day course.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0060400" scheme="gov.nih.nlm.semanticType.antb" label="cefixime"/>
			<category term="C0949665" scheme="gov.nih.nlm.semanticType.phsu" label="fluoroquinolones"/>
			<category term="C1136254" scheme="gov.nih.nlm.semanticType.phsu" label="antimicrobial"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H16"/>
			<id>211904</id>
			<summary>
				<section label="Duration" id="16">
					<fragment>Patients who are initially started on parenteral antibiotics should be switched to an oral regimen when able to take medications orally.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H17"/>
			<id>211905</id>
			<summary>
				<section label="Antiviral therapy" id="17">
					<fragment>Patients whose COPD exacerbation was triggered by influenza virus should be treated with antiviral therapy according to current recommendations and based on the predicted susceptibility patterns of the circulating strains.</fragment>
				</section>
			</summary>
			<category term="C0003451" scheme="gov.nih.nlm.semanticType.phsu" label="antiviral"/>
			<category term="C0280274" scheme="gov.nih.nlm.semanticType.topp" label="antiviral therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947517"/>
			<id>211908</id>
			<summary>
				<section label="Vaccination" id="489947517">
					<fragment>Patients with chronic obstructive pulmonary disease (COPD) should receive influenza vaccine annually and pneumococcal polysaccharide vaccine once, with a single booster five years later if the patient is &gt;=65 years old and was less than 65 years old when the initial vaccination was given: The utility of influenza vaccine is well established for reducing both the rate and severity of symptoms due to influenza, including respiratory symptoms.</fragment>
				</section>
			</summary>
			<category term="C0021403" scheme="gov.nih.nlm.semanticType.imft" label="influenza vaccine"/>
			<category term="C0032594" scheme="gov.nih.nlm.semanticType.phsu" label="polysaccharide"/>
			<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccination"/>
			<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
			<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="pneumococcal"/>
			<category term="C0857515" scheme="gov.nih.nlm.semanticType.topp" label="booster"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947517"/>
			<id>211909</id>
			<summary>
				<section label="Vaccination" id="489947517">
					<fragment>A meta-analysis of 11 trials, including six specifically performed in patients with COPD, found a significant reduction in the number of exacerbations per patient compared with placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947517"/>
			<id>211910</id>
			<summary>
				<section label="Vaccination" id="489947517">
					<fragment>For pneumococcal vaccine, a meta-analysis of seven trials that assessed the effect on patients with COPD found no evidence of a significant impact on morbidity or mortality.</fragment>
				</section>
			</summary>
			<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="pneumococcal"/>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947517"/>
			<id>211911</id>
			<summary>
				<section label="Vaccination" id="489947517">
					<fragment>One trial provided data on acute exacerbations of COPD, with no significant effect of vaccination, and a second trial found no significant effect on hospitalizations for acute exacerbations.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
			<category term="C0042196" scheme="gov.nih.nlm.semanticType.topp" label="vaccination"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947517"/>
			<id>211912</id>
			<summary>
				<section label="Vaccination" id="489947517">
					<fragment>The recommendation for the pneumococcal vaccine in patients with COPD is based upon studies suggesting a reduced frequency of pneumococcal pneumonia and pneumococcal bacteremia.</fragment>
				</section>
			</summary>
			<category term="C0042210" scheme="gov.nih.nlm.semanticType.imft" label="vaccine"/>
			<category term="C0305065" scheme="gov.nih.nlm.semanticType.imft" label="pneumococcal"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211913</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>Some clinicians advocate prophylactic antibiotics for patients with severe exacerbations, especially those that occur seasonally.</fragment>
				</section>
			</summary>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211916</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>Secondary outcomes of hospital admissions, change in lung function, serious adverse events, and mortality were not improved.</fragment>
				</section>
			</summary>
			<category term="C0184666" scheme="gov.nih.nlm.semanticType.hlca" label="hospital admissions"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211917</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>Two of the larger clinical trials included in the systematic review provide additional insight into the potential risks and benefits of prophylactic antibiotic therapy in carefully selected patients using newer antibiotic agents, and, in some cases, intermittent dosing regimens.</fragment>
				</section>
			</summary>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="prophylactic antibiotic therapy"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211918</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>In one such trial, 1157 patients with COPD at high risk for recurrent exacerbations were randomly assigned to receive either moxifloxacin or placebo;</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211920</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>The following observations were made: The patients who received moxifloxacin were less likely to have a COPD exacerbation in both the per-protocol analysis (OR 0.75, 95% CI 0.565-0.994) and in the intent-to-treat analysis (OR 0.81, 95% CI 0.645-1.008).</fragment>
				</section>
			</summary>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211924</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>In another trial, a significant reduction in the frequency of COPD exacerbations was observed among patients who received azithromycin prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211925</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>In this trial, 1142 patients with COPD were randomly assigned to receive azithromycin 250 mg orally daily or placebo for one year in addition to their usual COPD regimen.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211927</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>The following findings were observed: The median time to first COPD exacerbation was significantly longer among the patients who received azithromycin compared with those who received placebo (266 versus 174 days).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211928</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>Patients who received azithromycin had a significant (but modest) reduction in the frequency of COPD exacerbations compared with those who received placebo (1.48 versus 1.83 exacerbations per patient-year; hazard ratio 0.73, 95% CI 0.63-0.84).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211929</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>Patients who received azithromycin had a significantly higher rate of nasopharyngeal colonization with macrolide-resistant bacteria (Staphylococcus aureus [S. aureus], Streptococcus pneumoniae, Haemophilus spp, Moraxella spp) than those who received placebo (81 versus 41 percent).</fragment>
				</section>
			</summary>
			<category term="C0003240" scheme="gov.nih.nlm.semanticType.antb" label="macrolide"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211933</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>For most patients with COPD, we suggest not administering antibiotic prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211934</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>Only carefully selected patients, such as those who continue to have frequent exacerbations in spite of optimal therapy for their COPD with bronchodilators and antiinflammatory agents, should be considered for antibiotic prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211935</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>In such patients, we suggest prophylaxis with azithromycin.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211939</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>Suspected bacterial exacerbations in patients on antibiotic prophylaxis should be treated with antibiotics that are from a different class than the prophylactic agent.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="C1268823" scheme="gov.nih.nlm.semanticType.phsu" label="prophylactic agent"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H489947524"/>
			<id>211940</id>
			<summary>
				<section label="Prophylactic antibiotics" id="489947524">
					<fragment>Even if the regimen is successful in reducing exacerbations, interrupting treatment after 48 to 52 weeks should be considered.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H19"/>
			<id>211942</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>An exacerbation of chronic obstructive pulmonary disease (COPD) is an acute increase in symptoms beyond normal day-to-day variation.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H19"/>
			<id>211944</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Most exacerbations of COPD are due to respiratory infection or environmental pollution.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H19"/>
			<id>211947</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>Antibiotic therapy increases the likelihood of clinical improvement in patients having an exacerbation of COPD, particularly in patients with a moderate to severe exacerbation.</fragment>
				</section>
			</summary>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="Antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="Antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H19"/>
			<id>211951</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>The optimal antibiotic regimen for the treatment of exacerbations of COPD has not been determined.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H19"/>
			<id>211953</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>The initial antibiotic regimen should target likely bacterial pathogens and take into account local patterns of antibiotic resistance.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H19"/>
			<id>211954</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>The usual duration of antibiotic therapy is three to seven days, depending upon the response to therapy.</fragment>
				</section>
			</summary>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0338237" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic therapy"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H19"/>
			<id>211955</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>For most patients with COPD, we suggest not administering antibiotic prophylaxis.</fragment>
				</section>
			</summary>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/7019#H19"/>
			<id>211956</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="19">
					<fragment>For patients who continue to have frequent exacerbations despite optimal therapy for COPD with bronchodilators and antiinflammatory agents, we suggest antibiotic prophylaxis with azithromycin.</fragment>
				</section>
			</summary>
			<category term="C0003209" scheme="gov.nih.nlm.semanticType.phsu" label="antiinflammatory"/>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prophylaxis"/>
			<category term="C0282638" scheme="gov.nih.nlm.semanticType.topp" label="antibiotic prophylaxis"/>
			<category term="C0603045" scheme="gov.nih.nlm.semanticType.aapp" label="antibiotic"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Role of systemic glucocorticoid therapy in COPD</title>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C1261322" scheme="gov.nih.nlm.semanticType.hlca" label="clinical evaluation"/>
		<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0032950" scheme="gov.nih.nlm.semanticType.phsu" label="prednisolone"/>
		<category term="C0032950" scheme="gov.nih.nlm.semanticType.phsu" label="prednisolone"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
		<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screened"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0025815" scheme="gov.nih.nlm.semanticType.horm" label="methylprednisolone"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0032950" scheme="gov.nih.nlm.semanticType.phsu" label="prednisolone"/>
		<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
		<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
		<category term="C0032950" scheme="gov.nih.nlm.semanticType.phsu" label="prednisolone"/>
		<category term="C0054201" scheme="gov.nih.nlm.semanticType.phsu" label="budesonide"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
		<category term="C0441516" scheme="gov.nih.nlm.semanticType.topp" label="demand"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C1311032" scheme="gov.nih.nlm.semanticType.orch" label="GI"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C0455142" scheme="gov.nih.nlm.semanticType.topp" label="intravenous therapy"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
		<id>1438</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H2"/>
			<id>206887</id>
			<summary>
				<section label="RATIONALE" id="2">
					<fragment>Both systemic and inhaled glucocorticoids are widely prescribed for patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H2"/>
			<id>206888</id>
			<summary>
				<section label="RATIONALE" id="2">
					<fragment>In part, the use of these agents in the management of COPD has been an extension of their use in asthma.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H2"/>
			<id>206889</id>
			<summary>
				<section label="RATIONALE" id="2">
					<fragment>In addition, this approach has been based on hypotheses that glucocorticoids might suppress inflammatory processes unique to COPD.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H3"/>
			<id>206891</id>
			<summary>
				<section label="The asthma perspective" id="3">
					<fragment>Although most experts regard asthma and COPD as distinct diseases, some patients with obstructive lung disease cannot be clearly categorized even after careful clinical evaluation.</fragment>
				</section>
			</summary>
			<category term="C1261322" scheme="gov.nih.nlm.semanticType.hlca" label="clinical evaluation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H4"/>
			<id>206895</id>
			<summary>
				<section label="Inflammation and COPD" id="4">
					<fragment>Patients with COPD suffer from chronic destructive changes in the lungs, in addition to acute exacerbations.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H4"/>
			<id>206897</id>
			<summary>
				<section label="Inflammation and COPD" id="4">
					<fragment>The earliest lesion in smoking-related COPD may be chronic inflammation of distal airways, and inflammatory factors have also been proposed as a cause for some acute exacerbations.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H5"/>
			<id>206898</id>
			<summary>
				<section label="CLINICAL EVIDENCE" id="5">
					<fragment>The clinical value of systemic glucocorticoid therapy has been assessed both in patients with acute exacerbations, and in those with stable COPD.</fragment>
				</section>
			</summary>
			<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H6"/>
			<id>206900</id>
			<summary>
				<section label="Acute exacerbations" id="6">
					<fragment>Two major systematic reviews combined the results of double blind, randomized, placebo-controlled trials of systemic glucocorticoids in patients with acute exacerbations of COPD.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H7"/>
			<id>206904</id>
			<summary>
				<section label="Hospitalized patients" id="7">
					<fragment>Randomized trials have demonstrated that patients hospitalized for COPD exacerbations benefit from systemic glucocorticoid therapy.</fragment>
				</section>
			</summary>
			<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H7"/>
			<id>206906</id>
			<summary>
				<section label="Hospitalized patients" id="7">
					<fragment>However, examination of the data suggests that 10 to 14 day regimens of systemic glucocorticoid that begin with either a high or moderate dose can improve clinical outcomes.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H7"/>
			<id>206923</id>
			<summary>
				<section label="Hospitalized patients" id="7">
					<fragment>In this trial, 56 patients hospitalized for acute exacerbations were randomly assigned to receive either 30 mg of oral prednisolone or placebo daily for 14 days.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0032950" scheme="gov.nih.nlm.semanticType.phsu" label="prednisolone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H7"/>
			<id>206927</id>
			<summary>
				<section label="Hospitalized patients" id="7">
					<fragment>The 10-day group had greater improvements in the primary endpoints of FEV1 and PaO2 and a small but statistically significant improvement in dyspnea on exertion.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H7"/>
			<id>206932</id>
			<summary>
				<section label="Hospitalized patients" id="7">
					<fragment>To address the same question in hospitalized patients with COPD, a non-superiority trial of 210 patients compared regimens of intravenous versus oral prednisolone, 60 mg once daily for five days, followed by oral prednisolone in all patients.</fragment>
				</section>
			</summary>
			<category term="C0032950" scheme="gov.nih.nlm.semanticType.phsu" label="prednisolone"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H7"/>
			<id>206934</id>
			<summary>
				<section label="Hospitalized patients" id="7">
					<fragment>A potential confounding factor was that the large majority of patients (77 percent) had been treated with oral glucocorticoids in the 30 days prior to admission, though post-hoc subgroup analyses suggested that this did not influence the results.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H8"/>
			<id>206940</id>
			<summary>
				<section label="Outpatient exacerbations" id="8">
					<fragment>Patients received oral prednisone (40 mg) or placebo for ten days.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H8"/>
			<id>206941</id>
			<summary>
				<section label="Outpatient exacerbations" id="8">
					<fragment>Patients who received prednisone were less likely to return to the emergency department or their clinician with increasing dyspnea within 30 days (27 versus 43 percent).</fragment>
				</section>
			</summary>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H8"/>
			<id>206943</id>
			<summary>
				<section label="Outpatient exacerbations" id="8">
					<fragment>All of the studies in acute exacerbations excluded patients who had recently used systemic glucocorticoids, which in some cases eliminated nearly one-half of all screened patients.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screened"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H9"/>
			<id>206946</id>
			<summary>
				<section label="Stable COPD" id="9">
					<fragment>Aside from the studies described above, most information on systemic glucocorticoids in outpatients with COPD has been derived from small, short-term studies in stable patients.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H9"/>
			<id>206950</id>
			<summary>
				<section label="Stable COPD" id="9">
					<fragment>Forty-six stable outpatients with COPD received either oral methylprednisolone (32 mg per day) or placebo for two weeks in a double blind, crossover trial.</fragment>
				</section>
			</summary>
			<category term="C0025815" scheme="gov.nih.nlm.semanticType.horm" label="methylprednisolone"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H10"/>
			<id>206962</id>
			<summary>
				<section label="Clinical implications of prednisone response" id="10">
					<fragment>It appears unlikely that the response to a brief trial of oral glucocorticoids can predict which patients will have a more favorable response to chronic therapy with inhaled glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H10"/>
			<id>206964</id>
			<summary>
				<section label="Clinical implications of prednisone response" id="10">
					<fragment>The change in FEV1 during a 14 day trial of systemic glucocorticoid therapy (0.6 mg per kg oral prednisolone per day) did not predict the change in FEV1 over three years of subsequent therapy with inhaled fluticasone.</fragment>
				</section>
			</summary>
			<category term="C0032950" scheme="gov.nih.nlm.semanticType.phsu" label="prednisolone"/>
			<category term="C0082607" scheme="gov.nih.nlm.semanticType.phsu" label="fluticasone"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H10"/>
			<id>206966</id>
			<summary>
				<section label="Clinical implications of prednisone response" id="10">
					<fragment>Another question is whether responsiveness to prednisone might help to predict prognosis in COPD.</fragment>
				</section>
			</summary>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H10"/>
			<id>206967</id>
			<summary>
				<section label="Clinical implications of prednisone response" id="10">
					<fragment>In a year long trial, investigators studied a group of patients with COPD who had a significant FEV1 response following a two-week course of prednisolone . These prednisolone "responders", all of whom were treated with inhaled budesonide (800 mcg/day), were compared to similar patients without a significant initial response to prednisolone.</fragment>
				</section>
			</summary>
			<category term="C0032950" scheme="gov.nih.nlm.semanticType.phsu" label="prednisolone"/>
			<category term="C0054201" scheme="gov.nih.nlm.semanticType.phsu" label="budesonide"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H10"/>
			<id>206971</id>
			<summary>
				<section label="Clinical implications of prednisone response" id="10">
					<fragment>Despite continued efforts to study glucocorticoid responsiveness, definitive data on the role of glucocorticoid-response testing in COPD patients are lacking, perhaps due to the overall difficulty in assessing response or differences in patient populations tested.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H11"/>
			<id>206973</id>
			<summary>
				<section label="Chronic therapy" id="11">
					<fragment>Chronic daily doses of oral glucocorticoids have been prescribed for some patients.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H11"/>
			<id>206980</id>
			<summary>
				<section label="Chronic therapy" id="11">
					<fragment>There were no differences in exacerbations, spirometry, dyspnea, or health-related quality of life between the two groups during the six-month study, even though the demand group took considerably less prednisone than the continuous group.</fragment>
				</section>
			</summary>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C0441516" scheme="gov.nih.nlm.semanticType.topp" label="demand"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H13"/>
			<id>206986</id>
			<summary>
				<section label="term therapy and complications" id="13">
					<fragment>There is a general perception that short-term therapy, even at high doses, is relatively innocuous, but these effects have not been fully studied in patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H13"/>
			<id>206987</id>
			<summary>
				<section label="term therapy and complications" id="13">
					<fragment>The SCCOPE trial was the first to prospectively evaluate a number of specific complications in COPD patients treated with glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H13"/>
			<id>206988</id>
			<summary>
				<section label="term therapy and complications" id="13">
					<fragment>SCCOPE assessed the incidence of hyperglycemia, infections, hypertension, GI bleeding, and psychiatric disorders in patients treated with two-week and eight-week courses of systemic glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C1311032" scheme="gov.nih.nlm.semanticType.orch" label="GI"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H13"/>
			<id>206989</id>
			<summary>
				<section label="term therapy and complications" id="13">
					<fragment>Only hyperglycemia was more common in the glucocorticoid-treated groups, although part of the excess could be attributed to the fact that more diabetics were, by chance, assigned to the glucocorticoids groups.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H13"/>
			<id>206991</id>
			<summary>
				<section label="term therapy and complications" id="13">
					<fragment>The overall rate of infections observed in SCCOPE was no different among treatment groups, but patients who received the eight-week course of glucocorticoids had a tendency to have more severe infections, particularly pneumonia.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H13"/>
			<id>206992</id>
			<summary>
				<section label="term therapy and complications" id="13">
					<fragment>Other authors have reported severe infections related to immunosuppression in patients with COPD.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H13"/>
			<id>206993</id>
			<summary>
				<section label="term therapy and complications" id="13">
					<fragment>In addition, patients treated with short-term, high-dose glucocorticoids for septic shock have a significantly increased risk of secondary bacterial infection and an increased mortality.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H14"/>
			<id>206994</id>
			<summary>
				<section label="Risks of chronic therapy" id="14">
					<fragment>Prolonged courses of glucocorticoid therapy are generally thought to pose a greater risk for complications, particularly osteoporosis.</fragment>
				</section>
			</summary>
			<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H14"/>
			<id>206995</id>
			<summary>
				<section label="Risks of chronic therapy" id="14">
					<fragment>Systemic glucocorticoid therapy has been shown to be associated with a greater number and severity of vertebral fractures in COPD patients.</fragment>
				</section>
			</summary>
			<category term="C0744425" scheme="gov.nih.nlm.semanticType.topp" label="glucocorticoid therapy"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H15"/>
			<id>206997</id>
			<summary>
				<section label="Respiratory muscle dysfunction" id="15">
					<fragment>Human subjects with autoimmune disease have developed significant reductions in inspiratory strength and endurance after eight weeks of high-dose prednisone . One study in patients with COPD admitted to the hospital for exacerbations suggested that higher average daily doses of glucocorticoids prior to hospitalization caused reductions in inspiratory and quadriceps muscle strength.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0032952" scheme="gov.nih.nlm.semanticType.horm" label="prednisone"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H15"/>
			<id>206998</id>
			<summary>
				<section label="Respiratory muscle dysfunction" id="15">
					<fragment>Although not conclusive, these data raise additional concerns about glucocorticoid treatment in COPD patients.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H17"/>
			<id>207009</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="17">
					<fragment>Overall, benefits in acutely ill patients are modest and benefits in stable patients are uncommon, reflecting COPD as a generally non-glucocorticoid-sensitive process that is distinct from asthma.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H18"/>
			<id>207010</id>
			<summary>
				<section label="Acute exacerbations" id="18">
					<fragment>Systemic glucocorticoids hasten recovery, reduce hospital stay, and reduce early treatment failure in patients with acute exacerbations of COPD.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H18"/>
			<id>207012</id>
			<summary>
				<section label="Acute exacerbations" id="18">
					<fragment>shorter courses may achieve adequate outcomes but need further study.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H18"/>
			<id>207013</id>
			<summary>
				<section label="Acute exacerbations" id="18">
					<fragment>Although the optimum initial daily dose remains to be determined, there is no reason to believe that intravenous therapy is better than oral therapy for patients who are able to take oral medication.</fragment>
				</section>
			</summary>
			<category term="C0455142" scheme="gov.nih.nlm.semanticType.topp" label="intravenous therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H18"/>
			<id>207017</id>
			<summary>
				<section label="Acute exacerbations" id="18">
					<fragment>While the above studies provide a rationale for treating all patients with COPD exacerbations with a short course of systemic glucocorticoids, data from SCCOPE would support some targeting of therapy based on prior hospitalizations, risk of adverse effects and clinical response.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H18"/>
			<id>207018</id>
			<summary>
				<section label="Acute exacerbations" id="18">
					<fragment>Selected outpatients with acute exacerbations may also benefit from a course of systemic glucocorticoids.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H19"/>
			<id>207019</id>
			<summary>
				<section label="Stable COPD" id="19">
					<fragment>Since not all patients with obstructive lung disease can be placed in precise subgroups of COPD or asthma, it is likely that glucocorticoids will always have a role in selected patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1438#H19"/>
			<id>207025</id>
			<summary>
				<section label="Stable COPD" id="19">
					<fragment>By prescribing only a short course of systemic glucocorticoids when necessary for an individual exacerbation, applying some clinical skepticism in evaluating and treating "glucocorticoid-dependent" patients, and optimizing all other proven therapies, practitioners may be able to reduce the total systemic glucocorticoids exposure of COPD patients while achieving as good or better outcomes.</fragment>
				</section>
			</summary>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Role of anticholinergic therapy in COPD</title>
		<category term="C0002062" scheme="gov.nih.nlm.semanticType.phsu" label="alkaloids"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0036442" scheme="gov.nih.nlm.semanticType.phsu" label="scopolamine"/>
		<category term="C0304416" scheme="gov.nih.nlm.semanticType.phsu" label="naturally occurring alkaloids"/>
		<category term="C0002062" scheme="gov.nih.nlm.semanticType.phsu" label="alkaloid"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0304420" scheme="gov.nih.nlm.semanticType.phsu" label="belladonna"/>
		<category term="C0002062" scheme="gov.nih.nlm.semanticType.phsu" label="alkaloid"/>
		<category term="C0036442" scheme="gov.nih.nlm.semanticType.phsu" label="scopolamine"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevented"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0332293" scheme="gov.nih.nlm.semanticType.topp" label="treated by"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparations"/>
		<category term="C0351874" scheme="gov.nih.nlm.semanticType.topp" label="systemic preparations"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0014479" scheme="gov.nih.nlm.semanticType.phsu" label="ephedrine"/>
		<category term="C0242893" scheme="gov.nih.nlm.semanticType.phsu" label="cholinergic"/>
		<category term="C2935465" scheme="gov.nih.nlm.semanticType.phsu" label="ACh"/>
		<category term="C2935465" scheme="gov.nih.nlm.semanticType.phsu" label="ACh"/>
		<category term="C0062637" scheme="gov.nih.nlm.semanticType.phsu" label="hexamethonium"/>
		<category term="C0242948" scheme="gov.nih.nlm.semanticType.phsu" label="nicotinic agonists"/>
		<category term="C0242956" scheme="gov.nih.nlm.semanticType.phsu" label="nicotinic antagonists"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acts"/>
		<category term="C2935465" scheme="gov.nih.nlm.semanticType.phsu" label="ACh"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="Atropine"/>
		<category term="C0056003" scheme="gov.nih.nlm.semanticType.phsu" label="CNS"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevents"/>
		<category term="C2935465" scheme="gov.nih.nlm.semanticType.phsu" label="ACh"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="Atropine"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="Atropine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0030512" scheme="gov.nih.nlm.semanticType.phsu" label="parasympathomimetic drugs"/>
		<category term="C0600370" scheme="gov.nih.nlm.semanticType.phsu" label="methacholine"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C3179875" scheme="gov.nih.nlm.semanticType.phsu" label="compounds"/>
		<category term="C0036442" scheme="gov.nih.nlm.semanticType.phsu" label="scopolamine"/>
		<category term="C0069776" scheme="gov.nih.nlm.semanticType.phsu" label="Oxitropium"/>
		<category term="C0134499" scheme="gov.nih.nlm.semanticType.phsu" label="Oxitropium bromide"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C1174654" scheme="gov.nih.nlm.semanticType.orch" label="ethyl"/>
		<category term="C1306772" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium bromide"/>
		<category term="C3179875" scheme="gov.nih.nlm.semanticType.phsu" label="compounds"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipids"/>
		<category term="C0578399" scheme="gov.nih.nlm.semanticType.orch" label="quaternary ammonium compounds"/>
		<category term="C3179875" scheme="gov.nih.nlm.semanticType.phsu" label="compounds"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0308873" scheme="gov.nih.nlm.semanticType.phsu" label="dry"/>
		<category term="C0578399" scheme="gov.nih.nlm.semanticType.orch" label="quaternary ammonium compounds"/>
		<category term="C3179875" scheme="gov.nih.nlm.semanticType.phsu" label="compounds"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0056003" scheme="gov.nih.nlm.semanticType.phsu" label="CNS"/>
		<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
		<category term="C0001644" scheme="gov.nih.nlm.semanticType.phsu" label="beta-adrenergic agonist"/>
		<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C1512346" scheme="gov.nih.nlm.semanticType.hlca" label="encountered"/>
		<category term="C1627358" scheme="gov.nih.nlm.semanticType.topp" label="enhancement"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium"/>
		<category term="C0046401" scheme="gov.nih.nlm.semanticType.phsu" label="MDI"/>
		<category term="C0418991" scheme="gov.nih.nlm.semanticType.topp" label="metered dose inhaler"/>
		<category term="C0591130" scheme="gov.nih.nlm.semanticType.phsu" label="Atrovent"/>
		<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium bromide"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium"/>
		<category term="C0600370" scheme="gov.nih.nlm.semanticType.phsu" label="methacholine"/>
		<category term="C0048996" scheme="gov.nih.nlm.semanticType.phsu" label="HT"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0046401" scheme="gov.nih.nlm.semanticType.phsu" label="MDI"/>
		<category term="C0308779" scheme="gov.nih.nlm.semanticType.phsu" label="delivered"/>
		<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium bromide"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium"/>
		<category term="C2354695" scheme="gov.nih.nlm.semanticType.orch" label="gas"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0354764" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic bronchodilator"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
		<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
		<category term="C0001644" scheme="gov.nih.nlm.semanticType.phsu" label="beta-adrenergic agonists"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0029193" scheme="gov.nih.nlm.semanticType.phsu" label="metaproterenol"/>
		<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium bromide"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium bromide"/>
		<category term="C1875809" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetics"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium"/>
		<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="Anticholinergics"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="act"/>
		<category term="C1875809" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetics"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0029193" scheme="gov.nih.nlm.semanticType.phsu" label="metaproterenol"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="Tiotropium"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0308873" scheme="gov.nih.nlm.semanticType.phsu" label="dry"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="Tiotropium"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="Tiotropium"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0418986" scheme="gov.nih.nlm.semanticType.topp" label="respiratory medications"/>
		<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
		<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C3661274" scheme="gov.nih.nlm.semanticType.phsu" label="umeclidinium"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C2699757" scheme="gov.nih.nlm.semanticType.phsu" label="Aclidinium"/>
		<category term="C2699758" scheme="gov.nih.nlm.semanticType.phsu" label="Aclidinium bromide"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C2699757" scheme="gov.nih.nlm.semanticType.phsu" label="Aclidinium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="durations"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C2699757" scheme="gov.nih.nlm.semanticType.phsu" label="aclidinium"/>
		<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="Glycopyrronium"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="glycopyrronium"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="Glycopyrronium"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="glycopyrronium"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="glycopyrronium"/>
		<category term="C0026815" scheme="gov.nih.nlm.semanticType.phsu" label="muscarinic agents"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="glycopyrronium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0308873" scheme="gov.nih.nlm.semanticType.phsu" label="dry"/>
		<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
		<category term="C0069776" scheme="gov.nih.nlm.semanticType.phsu" label="Oxitropium"/>
		<category term="C0134499" scheme="gov.nih.nlm.semanticType.phsu" label="Oxitropium bromide"/>
		<category term="C0213769" scheme="gov.nih.nlm.semanticType.phsu" label="Ba 253 Br"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0354764" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic bronchodilator"/>
		<category term="C1289964" scheme="gov.nih.nlm.semanticType.phsu" label="quaternary anticholinergic"/>
		<category term="C1871913" scheme="gov.nih.nlm.semanticType.orch" label="Ba"/>
		<category term="C1956443" scheme="gov.nih.nlm.semanticType.orch" label="Br"/>
		<category term="C0076066" scheme="gov.nih.nlm.semanticType.phsu" label="Telenzepine"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C2699757" scheme="gov.nih.nlm.semanticType.phsu" label="aclidinium"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium bromide"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0308873" scheme="gov.nih.nlm.semanticType.phsu" label="dry"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C2352248" scheme="gov.nih.nlm.semanticType.orch" label="BPH"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0557055" scheme="gov.nih.nlm.semanticType.hlca" label="reassuring"/>
		<category term="C2352248" scheme="gov.nih.nlm.semanticType.orch" label="BPH"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C2352248" scheme="gov.nih.nlm.semanticType.orch" label="BPH"/>
		<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
		<category term="C2352248" scheme="gov.nih.nlm.semanticType.orch" label="BPH"/>
		<category term="C0242893" scheme="gov.nih.nlm.semanticType.phsu" label="cholinergic"/>
		<category term="C0443235" scheme="gov.nih.nlm.semanticType.topp" label="Impulses"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acts"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium"/>
		<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium bromide"/>
		<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
		<category term="C0001644" scheme="gov.nih.nlm.semanticType.phsu" label="beta-adrenergic agonists"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0308873" scheme="gov.nih.nlm.semanticType.phsu" label="dry"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C2699757" scheme="gov.nih.nlm.semanticType.phsu" label="Aclidinium"/>
		<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
		<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<id>1450</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H2"/>
			<id>207522</id>
			<summary>
				<section label="HISTORICAL PERSPECTIVE" id="2">
					<fragment>The most important of these naturally occurring alkaloids are atropine and scopolamine.</fragment>
				</section>
			</summary>
			<category term="C0002062" scheme="gov.nih.nlm.semanticType.phsu" label="alkaloids"/>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0036442" scheme="gov.nih.nlm.semanticType.phsu" label="scopolamine"/>
			<category term="C0304416" scheme="gov.nih.nlm.semanticType.phsu" label="naturally occurring alkaloids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H2"/>
			<id>207523</id>
			<summary>
				<section label="HISTORICAL PERSPECTIVE" id="2">
					<fragment>Atropa belladonna, the deadly nightshade, contains mainly the alkaloid atropine.</fragment>
				</section>
			</summary>
			<category term="C0002062" scheme="gov.nih.nlm.semanticType.phsu" label="alkaloid"/>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0304420" scheme="gov.nih.nlm.semanticType.phsu" label="belladonna"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H2"/>
			<id>207525</id>
			<summary>
				<section label="HISTORICAL PERSPECTIVE" id="2">
					<fragment>The alkaloid scopolamine (hyoscine) is found chiefly in the shrub Hyoscyamus niger (henbane) and Scopolia carniolica.</fragment>
				</section>
			</summary>
			<category term="C0002062" scheme="gov.nih.nlm.semanticType.phsu" label="alkaloid"/>
			<category term="C0036442" scheme="gov.nih.nlm.semanticType.phsu" label="scopolamine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H2"/>
			<id>207528</id>
			<summary>
				<section label="HISTORICAL PERSPECTIVE" id="2">
					<fragment>In 1867, Bezold and Bloebaum showed that atropine blocked the cardiac effects of vagal stimulation, and five years later Heidenhain found that it prevented salivary secretion produced by stimulation of the chorda tympani.</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevented"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H2"/>
			<id>207529</id>
			<summary>
				<section label="HISTORICAL PERSPECTIVE" id="2">
					<fragment>In 1859, it was reported that a severe asthma attack was successfully treated by injecting atropine into the vagus nerve.</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0332293" scheme="gov.nih.nlm.semanticType.topp" label="treated by"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H2"/>
			<id>207531</id>
			<summary>
				<section label="HISTORICAL PERSPECTIVE" id="2">
					<fragment>inhalational and systemic preparations of atropine were soon available for the treatment of asthma.</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparations"/>
			<category term="C0351874" scheme="gov.nih.nlm.semanticType.topp" label="systemic preparations"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H2"/>
			<id>207532</id>
			<summary>
				<section label="HISTORICAL PERSPECTIVE" id="2">
					<fragment>With the introduction of ephedrine and epinephrine during the 20th century, the use of atropine and related substances for relief of bronchospasm declined.</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0014479" scheme="gov.nih.nlm.semanticType.phsu" label="ephedrine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H3"/>
			<id>207535</id>
			<summary>
				<section label="PHYSIOLOGY AND PHARMACOLOGY" id="3">
					<fragment>The bulk of autonomic nerves in the human airways are branches of the vagus nerve, whose efferent preganglionic fibers enter the lung at the hilum and travel along the airways into the lung.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H3"/>
			<id>207537</id>
			<summary>
				<section label="PHYSIOLOGY AND PHARMACOLOGY" id="3">
					<fragment>Acetylcholine (ACh) is the endogenous neurotransmitter at cholinergic nerve endings, and its actions are mediated through nicotinic and muscarinic cholinergic receptors.</fragment>
				</section>
			</summary>
			<category term="C0242893" scheme="gov.nih.nlm.semanticType.phsu" label="cholinergic"/>
			<category term="C2935465" scheme="gov.nih.nlm.semanticType.phsu" label="ACh"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H4"/>
			<id>207539</id>
			<summary>
				<section label="Nicotinic receptors" id="4">
					<fragment>Nicotinic receptors are located on ganglionic neurons and are activated by ACh released from preganglionic vagal fibers.</fragment>
				</section>
			</summary>
			<category term="C2935465" scheme="gov.nih.nlm.semanticType.phsu" label="ACh"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H4"/>
			<id>207540</id>
			<summary>
				<section label="Nicotinic receptors" id="4">
					<fragment>These receptors are stimulated by nicotinic agonists and inhibited by nicotinic antagonists like hexamethonium.</fragment>
				</section>
			</summary>
			<category term="C0062637" scheme="gov.nih.nlm.semanticType.phsu" label="hexamethonium"/>
			<category term="C0242948" scheme="gov.nih.nlm.semanticType.phsu" label="nicotinic agonists"/>
			<category term="C0242956" scheme="gov.nih.nlm.semanticType.phsu" label="nicotinic antagonists"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207542</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>Muscarinic receptors are found primarily on the autonomic effector cells that are innervated by postganglionic parasympathetic nerves.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207544</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>At least three of these are expressed in the lung  : M1 receptors are present on peribronchial ganglion cells where the preganglionic nerves transmit to the postganglionic nerves.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207545</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>M2 receptors are present on the postganglionic nerves.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207546</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>M3 receptors are present on smooth muscle.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207548</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>Vagal fibers synapse and activate nicotinic and M1 muscarinic receptors in parasympathetic ganglia present in the airway wall.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207549</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>Short postganglionic fibers release ACh, which acts on M3 muscarinic receptors in airway smooth muscle.</fragment>
				</section>
			</summary>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acts"/>
			<category term="C2935465" scheme="gov.nih.nlm.semanticType.phsu" label="ACh"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207554</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>Atropine (the prototype of muscarinic receptor antagonists) prevents the effects of ACh by competitively blocking its binding to muscarinic receptors in the CNS, peripheral ganglia, and at neuroeffector sites on smooth muscle, cardiac muscle, and secretory glands.</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="Atropine"/>
			<category term="C0056003" scheme="gov.nih.nlm.semanticType.phsu" label="CNS"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevents"/>
			<category term="C2935465" scheme="gov.nih.nlm.semanticType.phsu" label="ACh"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207555</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>Atropine inhibits secretions of the nose, mouth, pharynx, and bronchi and thus causes dryness of the mucous membranes of the respiratory tract.</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="Atropine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207557</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>This depression of mucous secretion and the inhibition of mucociliary clearance, however, are undesirable side effects of atropine in patients with airway disease.</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207558</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>Atropine is particularly effective against bronchoconstriction produced by parasympathomimetic drugs such as methacholine;</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="Atropine"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0030512" scheme="gov.nih.nlm.semanticType.phsu" label="parasympathomimetic drugs"/>
			<category term="C0600370" scheme="gov.nih.nlm.semanticType.phsu" label="methacholine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207559</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>it also partially antagonizes bronchoconstriction induced by histamine and bradykinin.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H5"/>
			<id>207561</id>
			<summary>
				<section label="Muscarinic receptors" id="5">
					<fragment>As a result, extremely high doses of atropine or related drugs are required to produce any degree of blockade of the predominantly nicotinic receptors at the neuromuscular junction.</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H6"/>
			<id>207562</id>
			<summary>
				<section label="TERTIARY VERSUS QUATERNARY AGENTS" id="6">
					<fragment>Quaternary ammonium drugs (such as ipratropium) are synthetic derivatives of the naturally occurring tertiary ammonium compounds (such as atropine).</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C3179875" scheme="gov.nih.nlm.semanticType.phsu" label="compounds"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H6"/>
			<id>207564</id>
			<summary>
				<section label="TERTIARY VERSUS QUATERNARY AGENTS" id="6">
					<fragment>Other quaternary compounds include Oxitropium bromide (which is a derivative of scopolamine formed by the introduction of an ethyl group) and tiotropium bromide.</fragment>
				</section>
			</summary>
			<category term="C0036442" scheme="gov.nih.nlm.semanticType.phsu" label="scopolamine"/>
			<category term="C0069776" scheme="gov.nih.nlm.semanticType.phsu" label="Oxitropium"/>
			<category term="C0134499" scheme="gov.nih.nlm.semanticType.phsu" label="Oxitropium bromide"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C1174654" scheme="gov.nih.nlm.semanticType.orch" label="ethyl"/>
			<category term="C1306772" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium bromide"/>
			<category term="C3179875" scheme="gov.nih.nlm.semanticType.phsu" label="compounds"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H6"/>
			<id>207565</id>
			<summary>
				<section label="TERTIARY VERSUS QUATERNARY AGENTS" id="6">
					<fragment>The structure of the quaternary ammonium compounds renders them freely soluble in water but insoluble in lipids;</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipids"/>
			<category term="C0578399" scheme="gov.nih.nlm.semanticType.orch" label="quaternary ammonium compounds"/>
			<category term="C3179875" scheme="gov.nih.nlm.semanticType.phsu" label="compounds"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H6"/>
			<id>207567</id>
			<summary>
				<section label="TERTIARY VERSUS QUATERNARY AGENTS" id="6">
					<fragment>Most of the pharmacologic properties that distinguish quaternary ammonium compounds from atropine are due to this feature: The tertiary ammonium compounds are lipid-soluble, easily absorbed, and can cause significant side effects, including tachycardia, dry mouth, flushing of the skin, blurred vision, and mood changes.</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0308873" scheme="gov.nih.nlm.semanticType.phsu" label="dry"/>
			<category term="C0578399" scheme="gov.nih.nlm.semanticType.orch" label="quaternary ammonium compounds"/>
			<category term="C3179875" scheme="gov.nih.nlm.semanticType.phsu" label="compounds"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H6"/>
			<id>207573</id>
			<summary>
				<section label="TERTIARY VERSUS QUATERNARY AGENTS" id="6">
					<fragment>Unlike atropine, however, ipratropium lacks appreciable effect on the CNS, is poorly absorbed from the lungs or the gastrointestinal tract, and does not inhibit mucociliary clearance.</fragment>
				</section>
			</summary>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0056003" scheme="gov.nih.nlm.semanticType.phsu" label="CNS"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H6"/>
			<id>207574</id>
			<summary>
				<section label="TERTIARY VERSUS QUATERNARY AGENTS" id="6">
					<fragment>The use of ipratropium in patients with COPD therefore avoids the increased accumulation of lower airway secretions and the antagonism of beta-adrenergic agonist-induced enhancement of mucociliary clearance that is encountered with atropine.</fragment>
				</section>
			</summary>
			<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
			<category term="C0001644" scheme="gov.nih.nlm.semanticType.phsu" label="beta-adrenergic agonist"/>
			<category term="C0004259" scheme="gov.nih.nlm.semanticType.phsu" label="atropine"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C1512346" scheme="gov.nih.nlm.semanticType.hlca" label="encountered"/>
			<category term="C1627358" scheme="gov.nih.nlm.semanticType.topp" label="enhancement"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H7"/>
			<id>207577</id>
			<summary>
				<section label="IPRATROPIUM AS A SINGLE AGENT" id="7">
					<fragment>Ipratropium bromide (Atrovent) was first introduced to the United States in 1987 in a metered dose inhaler (MDI) form.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium"/>
			<category term="C0046401" scheme="gov.nih.nlm.semanticType.phsu" label="MDI"/>
			<category term="C0418991" scheme="gov.nih.nlm.semanticType.topp" label="metered dose inhaler"/>
			<category term="C0591130" scheme="gov.nih.nlm.semanticType.phsu" label="Atrovent"/>
			<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium bromide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H8"/>
			<id>207585</id>
			<summary>
				<section label="Dose" id="8">
					<fragment>Although the dose of the nebulized solution of ipratropium can be as low as 50 to 125 mcg, the dose may need to be increased for the treatment of acute bronchospasm.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H9"/>
			<id>207589</id>
			<summary>
				<section label="Efficacy" id="9">
					<fragment>However, patients with asthma and/or atopy are more responsive to these irritants and are less well protected.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H9"/>
			<id>207590</id>
			<summary>
				<section label="Efficacy" id="9">
					<fragment>Ipratropium also causes marked reduction in airway sensitivity to inhaled methacholine and a modest reduction in airway sensitivity from challenge with histamine or bradykinin;</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium"/>
			<category term="C0600370" scheme="gov.nih.nlm.semanticType.phsu" label="methacholine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H9"/>
			<id>207591</id>
			<summary>
				<section label="Efficacy" id="9">
					<fragment>however, it provides little protection against the bronchoconstriction induced by 5-HT or the leukotrienes.</fragment>
				</section>
			</summary>
			<category term="C0048996" scheme="gov.nih.nlm.semanticType.phsu" label="HT"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H9"/>
			<id>207592</id>
			<summary>
				<section label="Efficacy" id="9">
					<fragment>Administration of ipratropium bromide by MDI achieves its maximal effect in adults in a dose of 40 to 80 mcg, delivered by 2 to 4 actuations of the inhaler, or 50 to 125 mcg delivered by nebulizer.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0046401" scheme="gov.nih.nlm.semanticType.phsu" label="MDI"/>
			<category term="C0308779" scheme="gov.nih.nlm.semanticType.phsu" label="delivered"/>
			<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium bromide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H9"/>
			<id>207593</id>
			<summary>
				<section label="Efficacy" id="9">
					<fragment>Because penetration of inhaled particles into the airways is impaired when the airways are severely obstructed, higher doses may be needed for a maximal effect in patients with more severe airway disease.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H9"/>
			<id>207596</id>
			<summary>
				<section label="Efficacy" id="9">
					<fragment>Ipratropium has been shown to alleviate dyspnea, increase exercise tolerance, and improve gas exchange in patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium"/>
			<category term="C2354695" scheme="gov.nih.nlm.semanticType.orch" label="gas"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H9"/>
			<id>207599</id>
			<summary>
				<section label="Efficacy" id="9">
					<fragment>In this landmark study, the anticholinergic bronchodilator ipratropium was chosen as the bronchodilator of choice because of its low frequency of side effects, relatively long duration of action, and demonstrated bronchodilator efficacy in patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0354764" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic bronchodilator"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H9"/>
			<id>207604</id>
			<summary>
				<section label="Efficacy" id="9">
					<fragment>Since this effect is presumably available at any time during the course of disease, these results support the use of bronchodilators for symptomatic benefit, including relief of dyspnea and improvement in exercise tolerance.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H9"/>
			<id>207605</id>
			<summary>
				<section label="Efficacy" id="9">
					<fragment>By comparison, no treatment is needed in asymptomatic patients, as therapy does not alter the natural history of the disorder.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H10"/>
			<id>207606</id>
			<summary>
				<section label="AGONISTS" id="10">
					<fragment>In COPD, ipratropium has been shown to be superior to the beta-adrenergic agonists in both short- and long-term studies.</fragment>
				</section>
			</summary>
			<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
			<category term="C0001644" scheme="gov.nih.nlm.semanticType.phsu" label="beta-adrenergic agonists"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H10"/>
			<id>207607</id>
			<summary>
				<section label="AGONISTS" id="10">
					<fragment>As an example, in a multicenter, randomized trial of 260 patients with COPD but no asthma or atopy, ipratropium was more potent at its peak effect and was longer acting than metaproterenol  . Similar findings were also reported for nebulized ipratropium bromide.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0029193" scheme="gov.nih.nlm.semanticType.phsu" label="metaproterenol"/>
			<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium bromide"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H10"/>
			<id>207608</id>
			<summary>
				<section label="AGONISTS" id="10">
					<fragment>In addition, some studies have shown that ipratropium bromide produced significant bronchodilation in patients who did not respond to inhaled sympathomimetics.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium bromide"/>
			<category term="C1875809" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H10"/>
			<id>207609</id>
			<summary>
				<section label="AGONISTS" id="10">
					<fragment>Ipratropium therapy may also result in an improvement in the quality of life of patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H10"/>
			<id>207610</id>
			<summary>
				<section label="AGONISTS" id="10">
					<fragment>In a multicenter, randomized trial of 223 patients with COPD, the efficacy of nebulized ipratropium (500 mcg) was compared to nebulized albuterol (2.5 mg) (each taken 3 times daily for up to 83 days).</fragment>
				</section>
			</summary>
			<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H10"/>
			<id>207612</id>
			<summary>
				<section label="AGONISTS" id="10">
					<fragment>Although the side effects of inhaled beta-2 agonists are generally minor, they may produce troublesome tremor in the dosages required to produce bronchodilation in COPD.</fragment>
				</section>
			</summary>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H10"/>
			<id>207613</id>
			<summary>
				<section label="AGONISTS" id="10">
					<fragment>In addition, beta-2 agonist use in patients with COPD may be accompanied by pulmonary vasodilation, which may worsen ventilation-perfusion matching and result in a slight fall in arterial PaO2.</fragment>
				</section>
			</summary>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="fall"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H11"/>
			<id>207616</id>
			<summary>
				<section label="COMBINATION THERAPY" id="11">
					<fragment>Several physiologic reasons exist for the potential benefit of combination therapy with ipratropium and beta agonists: Anticholinergics act predominantly on the proximal large airways, while sympathomimetics act on the more distal small airways.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="Anticholinergics"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="act"/>
			<category term="C1875809" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H11"/>
			<id>207620</id>
			<summary>
				<section label="COMBINATION THERAPY" id="11">
					<fragment>When recommended doses of bronchodilators are used in COPD, the administration of combinations of agents generally results in more bronchodilation than does the administration of single agents.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilators"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H11"/>
			<id>207622</id>
			<summary>
				<section label="COMBINATION THERAPY" id="11">
					<fragment>In patients with COPD, this offers a potential therapeutic advantage over nebulized metaproterenol alone without a risk of increased side effects.</fragment>
				</section>
			</summary>
			<category term="C0029193" scheme="gov.nih.nlm.semanticType.phsu" label="metaproterenol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207625</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>Tiotropium ) is a long-acting anticholinergic agent with M1 and M3 selectivity  . In the United States it is administered via a dry powder inhaler 18 mcg/day, while in other countries it is administered via a soft mist inhaler (Respimat), 2 inhalations of 2.5 mcg/day.</fragment>
				</section>
			</summary>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="Tiotropium"/>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C0308873" scheme="gov.nih.nlm.semanticType.phsu" label="dry"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207628</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>Tiotropium is longer acting than ipratropium and may allow a more convenient dosing schedule for patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="Tiotropium"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207629</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>One study randomized 288 patients with severe COPD to receive either tiotropium once per day or ipratropium four times per day.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207631</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>Continuous therapy with tiotropium appears to be well tolerated, and is associated with decreased dyspnea, improved quality of life, fewer acute exacerbations, a reduction in hyperinflation, and improved overnight arterial oxygen saturation compared to placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207636</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>This was demonstrated in a large randomized controlled trial comparing one year of therapy with tiotropium to placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207637</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>The presence or absence of a bronchodilator response on the first day of treatment did not predict long-term outcome, and patients treated with tiotropium had improved spirometry and less subjective dyspnea than control patients regardless of the response to the first dose.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207638</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>In a systematic review that compared tiotropium with ipratropium in patients with COPD (n = 1073), tiotropium was associated with improved lung function, fewer hospitalizations, fewer exacerbations of COPD, and improved quality of life.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207640</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>Tiotropium, like ipratropium, appears to provide superior bronchodilation and improvements in dyspnea when compared with long-acting beta-agonists in patients with stable disease.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="Tiotropium"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207641</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>This was demonstrated in a large three-armed trial comparing tiotropium with the long-acting beta-agonist salmeterol and placebo in over 1200 patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207642</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>Therapy with tiotropium resulted in a significant delay in the time until first exacerbation, and fewer exacerbations per year, than treatment with salmeterol or placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207643</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>Over the long-term, tiotropium improves lung function and quality of life, and also decreases the risk of exacerbations, but does not reduce the rate of decline in forced expiratory volume in one second (FEV1).</fragment>
				</section>
			</summary>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H12"/>
			<id>207645</id>
			<summary>
				<section label="TIOTROPIUM" id="12">
					<fragment>Patients were allowed to take other respiratory medications, as needed.</fragment>
				</section>
			</summary>
			<category term="C0418986" scheme="gov.nih.nlm.semanticType.topp" label="respiratory medications"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H3755024"/>
			<id>207651</id>
			<summary>
				<section label="UMECLIDINIUM" id="3755024">
					<fragment>All three doses of umeclidinium significantly increased trough FEV1 (150 to 160 mL) at 24 hours after the last dose on days 2, 14, 28, and 29, and also reduced rescue salmeterol (albuterol) use during the study.</fragment>
				</section>
			</summary>
			<category term="C0001927" scheme="gov.nih.nlm.semanticType.phsu" label="albuterol"/>
			<category term="C0073992" scheme="gov.nih.nlm.semanticType.phsu" label="salmeterol"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C3661274" scheme="gov.nih.nlm.semanticType.phsu" label="umeclidinium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H1814588"/>
			<id>207656</id>
			<summary>
				<section label="ACLIDINIUM" id="1814588">
					<fragment>Aclidinium bromide is a long-acting anticholinergic agent that selectively inhibits the M3 muscarinic receptor.</fragment>
				</section>
			</summary>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C2699757" scheme="gov.nih.nlm.semanticType.phsu" label="Aclidinium"/>
			<category term="C2699758" scheme="gov.nih.nlm.semanticType.phsu" label="Aclidinium bromide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H1814588"/>
			<id>207657</id>
			<summary>
				<section label="ACLIDINIUM" id="1814588">
					<fragment>Aclidinium is longer acting than ipratropium, but shorter acting than tiotropium.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C2699757" scheme="gov.nih.nlm.semanticType.phsu" label="Aclidinium"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H1814588"/>
			<id>207667</id>
			<summary>
				<section label="ACLIDINIUM" id="1814588">
					<fragment>Larger studies with longer treatment durations are needed to provide meaningful comparisons between aclidinium, tiotropium, and the long-acting beta agonists.</fragment>
				</section>
			</summary>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="durations"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C2699757" scheme="gov.nih.nlm.semanticType.phsu" label="aclidinium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H89640776"/>
			<id>207671</id>
			<summary>
				<section label="GLYCOPYRRONIUM" id="89640776">
					<fragment>Glycopyrronium, known by the generic name glycopyrrolate in the United States, is a long-acting anticholinergic agent that selectively inhibits muscarinic receptors in bronchial smooth muscle with greater affinity for M1 and M3, than M2.</fragment>
				</section>
			</summary>
			<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="Glycopyrronium"/>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H89640776"/>
			<id>207675</id>
			<summary>
				<section label="GLYCOPYRRONIUM" id="89640776">
					<fragment>No patients on placebo had AF.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H89640776"/>
			<id>207677</id>
			<summary>
				<section label="GLYCOPYRRONIUM" id="89640776">
					<fragment>At week 12, the trough FEV1 was increased over placebo by 97 mL (95% CI 64.6-130.2) with glycopyrronium and 83 mL (95% CI 45.6-121.4) with tiotropium.</fragment>
				</section>
			</summary>
			<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="glycopyrronium"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H89640776"/>
			<id>207678</id>
			<summary>
				<section label="GLYCOPYRRONIUM" id="89640776">
					<fragment>Glycopyrronium was also associated with significant improvement in dyspnea and reduction in exacerbations relative to placebo.</fragment>
				</section>
			</summary>
			<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="Glycopyrronium"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H89640776"/>
			<id>207679</id>
			<summary>
				<section label="GLYCOPYRRONIUM" id="89640776">
					<fragment>AF occurred in four patients (0.8 percent) in the glycopyrronium group and none in the placebo or tiotropium groups.</fragment>
				</section>
			</summary>
			<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="glycopyrronium"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0050909" scheme="gov.nih.nlm.semanticType.orch" label="AF"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H89640776"/>
			<id>207680</id>
			<summary>
				<section label="GLYCOPYRRONIUM" id="89640776">
					<fragment>Additional, larger studies are needed to ascertain the safety of long-term inhaled glycopyrronium and to provide meaningful efficacy and safety comparisons with the other long-acting muscarinic agents and long-acting beta agonists.</fragment>
				</section>
			</summary>
			<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="glycopyrronium"/>
			<category term="C0026815" scheme="gov.nih.nlm.semanticType.phsu" label="muscarinic agents"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H89640776"/>
			<id>207682</id>
			<summary>
				<section label="GLYCOPYRRONIUM" id="89640776">
					<fragment>In a trial that compared glycopyrronium with tiotropium, dry mouth was slightly more common with inhaled glycopyrronium than tiotropium, but urinary infection was slightly more common with tiotropium, than glycopyrronium.</fragment>
				</section>
			</summary>
			<category term="C0017970" scheme="gov.nih.nlm.semanticType.phsu" label="glycopyrronium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0308873" scheme="gov.nih.nlm.semanticType.phsu" label="dry"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H13"/>
			<id>207683</id>
			<summary>
				<section label="OTHER AGENTS" id="13">
					<fragment>Several additional quaternary anticholinergic agents are currently being evaluated for a potential role in the treatment of patients with COPD: Oxitropium bromide (Ba 253 Br) is an effective anticholinergic bronchodilator that inhibits all 3 muscarinic airway receptors.</fragment>
				</section>
			</summary>
			<category term="C0006280" scheme="gov.nih.nlm.semanticType.phsu" label="bronchodilator"/>
			<category term="C0069776" scheme="gov.nih.nlm.semanticType.phsu" label="Oxitropium"/>
			<category term="C0134499" scheme="gov.nih.nlm.semanticType.phsu" label="Oxitropium bromide"/>
			<category term="C0213769" scheme="gov.nih.nlm.semanticType.phsu" label="Ba 253 Br"/>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C0354764" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic bronchodilator"/>
			<category term="C1289964" scheme="gov.nih.nlm.semanticType.phsu" label="quaternary anticholinergic"/>
			<category term="C1871913" scheme="gov.nih.nlm.semanticType.orch" label="Ba"/>
			<category term="C1956443" scheme="gov.nih.nlm.semanticType.orch" label="Br"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H13"/>
			<id>207685</id>
			<summary>
				<section label="OTHER AGENTS" id="13">
					<fragment>Telenzepine is an experimental M1-selective muscarinic receptor antagonist that has been found to improve lung function in patients with nocturnal asthma but not in those with COPD.</fragment>
				</section>
			</summary>
			<category term="C0076066" scheme="gov.nih.nlm.semanticType.phsu" label="Telenzepine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H14"/>
			<id>207688</id>
			<summary>
				<section label="POTENTIAL RISKS" id="14">
					<fragment>Systemic absorption of ipratropium, tiotropium, and aclidinium from the mouth and gastrointestinal tract is low, although some absorption from the lung does occur.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C2699757" scheme="gov.nih.nlm.semanticType.phsu" label="aclidinium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301605"/>
			<id>207690</id>
			<summary>
				<section label="Cardiovascular effects" id="91301605">
					<fragment>Despite the minimal impact of ipratropium and tiotropium on heart rate and blood pressure, concern has been raised regarding possible adverse cardiovascular effects in patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301605"/>
			<id>207697</id>
			<summary>
				<section label="Cardiovascular effects" id="91301605">
					<fragment>In a prior meta-analysis of 17 randomized trials enrolling nearly 15,000 patients, but not including the UPLIFT trial, the use of ipratropium or tiotropium for more than 30 days significantly increased the risk of myocardial infarction (RR 1.53 [95% CI, 1.05 to 2.23]) and cardiovascular death (RR 1.80 [95% CI, 1.17 to 2.77]).</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301605"/>
			<id>207698</id>
			<summary>
				<section label="Cardiovascular effects" id="91301605">
					<fragment>There remains the possibility that ipratropium bromide and tiotropium have different effects on cardiovascular events.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium bromide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301605"/>
			<id>207699</id>
			<summary>
				<section label="Cardiovascular effects" id="91301605">
					<fragment>The potential effect of ipratropium on cardiovascular events was examined in a cohort study of 82,717 United States veterans with COPD who were followed from 1999 to 2002.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301605"/>
			<id>207700</id>
			<summary>
				<section label="Cardiovascular effects" id="91301605">
					<fragment>The hazard ratio for cardiovascular events among patients who had four or fewer 30 day prescriptions for ipratropium was 1.40 [95% CI 1.30-1.51], and the hazard ratio among those with more than four 30 day prescriptions was 1.23 [95% CI 1.13-1.36].</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H283474958"/>
			<id>207705</id>
			<summary>
				<section label="Mortality" id="283474958">
					<fragment>A systematic review raised concern about a possible increase in mortality associated with the tiotropium soft mist inhaler in patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H283474958"/>
			<id>207711</id>
			<summary>
				<section label="Mortality" id="283474958">
					<fragment>In this trial, 17,135 patients with COPD were randomly assigned to Respimat 2.5 or 5 mcg/day or dry powder inhaler 18 mcg/day.</fragment>
				</section>
			</summary>
			<category term="C0308873" scheme="gov.nih.nlm.semanticType.phsu" label="dry"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H283474958"/>
			<id>207714</id>
			<summary>
				<section label="Mortality" id="283474958">
					<fragment>While patients with cardiac arrhythmia, ischemic heart disease, and coronary heart disease were included, those with unstable cardiovascular conditions (class III or IV heart failure, myocardial infarction in the prior six months) or moderate or severe renal failure were excluded.</fragment>
				</section>
			</summary>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301509"/>
			<id>207716</id>
			<summary>
				<section label="Acute urinary retention" id="91301509">
					<fragment>Systemic absorption of inhaled anticholinergic agents has the potential to increase the risk of acute urinary retention in susceptible patients such as those with benign prostatic hypertrophy (BPH) or lower urinary tract symptoms.</fragment>
				</section>
			</summary>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C2352248" scheme="gov.nih.nlm.semanticType.orch" label="BPH"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301509"/>
			<id>207720</id>
			<summary>
				<section label="Acute urinary retention" id="91301509">
					<fragment>A nested case control study of 565,073 older adults with COPD examined the risk of acute urinary retention associated with use of inhaled anticholinergic agents.</fragment>
				</section>
			</summary>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301509"/>
			<id>207722</id>
			<summary>
				<section label="Acute urinary retention" id="91301509">
					<fragment>A separate nested case-control study of 22,579 patients with COPD found an increased risk of acute urinary retention among those on inhaled anticholinergic agents (adjusted odds ratio 1.40, 95% CI 0.99-1.98) compared with non-users.</fragment>
				</section>
			</summary>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301509"/>
			<id>207723</id>
			<summary>
				<section label="Acute urinary retention" id="91301509">
					<fragment>The risk associated with ipratropium did not appear different from that associated with tiotropium.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301509"/>
			<id>207724</id>
			<summary>
				<section label="Acute urinary retention" id="91301509">
					<fragment>On the other hand, reassuring data comes from these studies: The UPLIFT trial that randomly assigned approximately 6000 patients with COPD to tiotropium or placebo for four years included patients with BPH whose symptoms were controlled with treatment.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0557055" scheme="gov.nih.nlm.semanticType.hlca" label="reassuring"/>
			<category term="C2352248" scheme="gov.nih.nlm.semanticType.orch" label="BPH"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301509"/>
			<id>207726</id>
			<summary>
				<section label="Acute urinary retention" id="91301509">
					<fragment>Among 25 patients with COPD and BPH, use of tiotropium for months was not associated with any cases of acute urinary retention nor urinary parameters such as maximal flow rate (Q-max), average flow rate (Q-ave), postvoid residual urine volume (PVR), or bladder voiding efficiency (BVE).</fragment>
				</section>
			</summary>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C2352248" scheme="gov.nih.nlm.semanticType.orch" label="BPH"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H91301509"/>
			<id>207728</id>
			<summary>
				<section label="Acute urinary retention" id="91301509">
					<fragment>We are cautious when initiating inhaled anticholinergic therapy in patients with known BPH and advise patients to report any changes in urinary function.</fragment>
				</section>
			</summary>
			<category term="C0242896" scheme="gov.nih.nlm.semanticType.phsu" label="anticholinergic"/>
			<category term="C2352248" scheme="gov.nih.nlm.semanticType.orch" label="BPH"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H16"/>
			<id>207739</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>Impulses from the vagus nerve lead to secretion of acetylcholine, which in turn acts through nicotinic and muscarinic cholinergic receptors on airway smooth muscle and tracheobronchial submucosal glands.</fragment>
				</section>
			</summary>
			<category term="C0242893" scheme="gov.nih.nlm.semanticType.phsu" label="cholinergic"/>
			<category term="C0443235" scheme="gov.nih.nlm.semanticType.topp" label="Impulses"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acts"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H16"/>
			<id>207740</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>The muscarinic receptors M1 and M3 on airway smooth muscle cells mediate the parasympathetic bronchoconstrictive effect of the vagus nerve ).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H16"/>
			<id>207741</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>M2 receptors are located on postganglionic nerves;</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H16"/>
			<id>207742</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>activation of M2 receptors limits further production of acetylcholine and protects against bronchoconstriction mediated via the parasympathetic nerves.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H16"/>
			<id>207745</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>Ipratropium bromide is an inhaled quaternary ammonium that blocks all three muscarinic receptors (M1, M2, M3).</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium"/>
			<category term="C0700580" scheme="gov.nih.nlm.semanticType.phsu" label="Ipratropium bromide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H16"/>
			<id>207747</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>In COPD, ipratropium is superior to the beta-adrenergic agonists in both short- and long-term studies of acute bronchodilation and in long-term improvement in dyspnea and quality of life.</fragment>
				</section>
			</summary>
			<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
			<category term="C0001644" scheme="gov.nih.nlm.semanticType.phsu" label="beta-adrenergic agonists"/>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H16"/>
			<id>207750</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>Nonetheless, in COPD, it provides superior long-term bronchodilation compared to ipratropium.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H16"/>
			<id>207751</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>It also reduces the frequency of exacerbations and hospitalizations, and improves dyspnea when compared with long-acting beta-agonists.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalizations"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H16"/>
			<id>207752</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>Aclidinium, administered by dry powder inhaler, is more long-acting than ipratropium, but shorter acting than tiotropium.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0308873" scheme="gov.nih.nlm.semanticType.phsu" label="dry"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C2699757" scheme="gov.nih.nlm.semanticType.phsu" label="Aclidinium"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1450#H16"/>
			<id>207754</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="16">
					<fragment>Despite the minimal impact of ipratropium and tiotropium on heart rate and blood pressure, data are conflicting regarding possible adverse cardiovascular effects of these agents in patients with COPD.</fragment>
				</section>
			</summary>
			<category term="C0027235" scheme="gov.nih.nlm.semanticType.phsu" label="ipratropium"/>
			<category term="C0213771" scheme="gov.nih.nlm.semanticType.phsu" label="tiotropium"/>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
</aggregateKnowledgeResponse>
